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1. INTRODUCTION
Inflammatory bowel disease (IBD) encompasses two distinct disease entities, 
ulcerative colitis (UC) and Crohn’s disease (CD). Despite extensive investiga­
tions over several decades, there is still no simple explanation formulated for 
the cause of these disorders. It is likely because of the pathogenesis of IBD, 
which is more complex than a single cause and effect relation, and probably 
represents an interaction between genetic predisposing factors, exogenous 
triggers, and modifying factors (1-4). The outcome of these interactions is a 
spontaneously relapsing and remitting inflammatory process in which tissue 
injury is mediated by the immune system (3, 5).
IBD is relatively common in most industrialised countries in the world. The 
incidence varies greatly geographically and ranges from about 1 to 10 per
100,000 per year for CD and from 5 to 18 for UC. The highest rates are reported 
in the Scandinavian countries and Scotland, followed by England and North 
America, whereas IBD seems to be less common in Central and Southern 
Europe and appears to be uncommon in developing countries (6, 7). The disease 
affects equally men and women of all ages, and mainly manifests during late 
adolescence or early adulthood with a peak onset between 15 and 30 years of 
age.
The basis for the present studies was an epidemiological investigation of the 
incidence and prevalence of UC and CD in Tartu County, Estonia. A retro­
spective study of Salupere R. et al. (8-10) for 1973-1993 revealed that IBD is 
not so common in Estonia as it is in other countries. The annual incidence of 
UC for this period was 1.5 cases per 100,000 and of CD 0.3 per 100,000. The 
reasons for such low incidence in Estonia are not clear.
Since there are substantial epidemiological differences in the incidence of 
IBD between Estonia and European countries, then only with the help of 
additional studies more data would be received about specific features of IBD in 
Estonia.
To ascertain an association between IBD and autoimmunity, the frequency 
and clinical value of antineutrophil cytoplasmic antibodies (ANCA) and several 
non-organ-specific antibodies in the patients with IBD are analysed in the first 
part of the study.
In the second part of the current study we examined the frequency of anti­
gliadin antibodies (AGA), antireticulin antibodies (ARA), and antiendomysium 
antibodies (AEM) in the patients with UC and evaluated the correlations be­
tween these antibodies and various clinical features. Whereas the association of 
coeliac disease and UC has been reported by several authors (11—13). Further­
more, the association of IBD with known autoimmune diseases and the frequent 
occurrence of extraintestinal manifestations which share all the essential 
characteristics of their idiopathic counterparts and thus probably represent
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autoimmune diseases as well, can be regarded as indirect evidence for the 
occurrence of autoimmune mechanisms in the context of IBD.
In the third part of the present study the role of several immunogenetic 
markers — the polymorphisms of HLA-DR and -DQ, tumour necrosis factor 
(TNF), E-selectin, L-selectin and intercellular adhesion molecule 1 (ICAM-1) 
have been investigated and the associations of these markers with the ANCA 
status in the patients with IBD was determined.
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2. REVIEW OF LITERATURE
2.1. Definition, clinical features, course, therapy and 
outcome of ulcerative colitis
Ulcerative colitis is an inflammatory disease of the colonic mucosa of unknown 
aetiology. The disease is variable both in the extent and the severity of the 
involvement of the colon. The inflammation may be found in the rectum only 
(proctitis), or proximally up to the mid-transverse colon (left-sided colitis), or 
engaging the whole of the colon and rectum (extensive colitis or total colitis). 
The spectrum of severity ranges from mild inflammation to florid ulceration and 
haemorrhage extending into, and sometimes through, the full thickness of the 
colonic wall leading to perforation.
The most common signs of the UC relapse are hematochezia (visible blood 
in the stool) and diarrhoea. These symptoms are present in more than 80% of 
patients at the onset of their disease (14-16). Abdominal pain, rectal cramps and 
fever may occur at the time of diagnosis. More severely ill patients lose weight 
and develop anaemia (17). The onset of UC may be sudden with bloody 
diarrhoea appearing within a few days, but the usual mode of onset is more gra­
dual with diarrhoea progressing from increased frequency of stool to frequent 
bloody liquid movements over a period of several weeks.
Approximately 30% of UC patients have the disease limited to the rectum, in 
about 40% the disease extends above the rectum but not beyond the hepatic 
flexure, and the remaining 30% develop total colitis at their first attack (14, 17, 
18).
The course of UC is characterised by an intermittent course with remission 
and relapses in 90% of the patients (17, 19-21). A small minority never achieve 
satisfactory remission and continue with symptoms to greater or lesser degree.
One or more extraintestinal complications of the disease may occur during a 
life-long course. In a population-based study by Monsen et al. (22), the overall 
prevalence of extracolonic diagnoses was 21%, whereas 70% of these patients 
had extensive colitis. The most common extracolonic diagnoses were arthritis, 
ankylosing spondylitis, iritis, skin lesions (erythema nodosum, pyoderma gan­
grenosum) and hepatobiliary complications (primary sclerosing cholangitis).
Sulphasalazine was introduced for the treatment of UC in the early 40’s (23). 
It was found later that the active moiety of sulphasalazine is the 5-aminosali- 
cylic acid (5-ASA) (24). Several new types of 5-ASA or 5-ASA prodrugs are 
now available, although the exact mechanism(s) of their action remain unclear. 
Comparative trials of sulphasalazine and a variety of 5-ASA formulations have, 
as anticipated, demonstrated therapeutic equivalence but improved tolerance 
with 5-ASA (25). 5-ASA is effective at both the induction and maintenance of 
remission (26, 27). Corticosteroids were introduced in the mid 50’s as the
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treatment for severe attacks of UC (28) and are still the most commonly used 
agents for the treatment of moderate to severe inflammatory activity in UC (29).
Approximately 20% of the patients will undergo colectomy within 10 years, 
30% within 25 years (21, 30), whereas the colectomy rate is highest during the 
first year after onset of disease and the main indication for early surgery is the 
failure of medical treatment. Later on the main indication for surgery is the 
cancer prophylaxis (31). As known, UC is associated with increased incidence 
of both colonic and extracolonic neoplasms (32, 33). The risk of developing 
cancer is closely related to the extent and duration of the disease, as well as 
colectomy also influences the risk for cancer. The cumulative risk of developing 
colonic cancer in two recent reports in patients with extensive colitis at 25 years 
was 3% and 10% (34, 35), respectively.
Advances in the diagnosis and management of the disease have substantially 
modified its natural history. When compared with the general population, 
Edwards and Traelove in their classic study (19) found a two-fold excess mor­
tality in patients with UC. Langholz et al. (35), reporting 25 years later, showed 
the risk of death in the first year (<0.8%), reflecting a small number of patients 
with severe acute extensive colitis. After the first year, there was no significant 
difference in survival between patients with colitis and a background-matched 
population.
2.2. Definition, clinical features, course, therapy and 
outcome of Crohn’s disease
Crohn’s disease is a transmural chronic inflammation of unknown origin. It is 
usually segmental and may affect any part of the gastrointestinal tract from 
mouth to anus. It is, however, most commonly located to the ileocecal region.
The clinical features on the presentation are diverse and depend directly on 
the location of inflammation as well as the individual’s reaction to that inflam­
mation.
Approximately 40% of CD patients will present with ileocecal disease; the 
principal symptoms are diarrhoea, cramping abdominal pain, and low-grade 
fever. On a physical examination there is tenderness and often an abdominal 
mass in the right lower quadrant of the abdomen.
The disease limited to the small bowel is observed in approximately 30% of 
patients with CD. Small bowel extensive disease can lead to the loss of the 
effective absorptive surface with the resultant malabsorption syndrome and 
steatorrhoea. Weight loss and growth retardation in children may develop.
The exclusive colonic Crohn’s disease is seen in approximately 25% of CD 
patients. Diarrhoea and hematochezia are the most common presenting features
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of CD, with the volume of diarrhoea and the proportion of patients with 
bleeding in CD usually less than in UC.
Fistulae in the anorectal region or from the affected bowel segment to other 
organs or the skin may appear. Abscesses and other perianal lesions are also 
common.
Approximately 5% of patients with CD present with clinical findings that are 
not typical.
CD is a naturally remitting and relapsing disease and the patterns of the 
disease activity may vary from a patient to patient. It appears, however, that the 
course within the first two years after diagnosis indicates a close correlation to 
the course during the subsequent 5 years (36). As in UC, also in CD, extraintes- 
tinal manifestations such as arthritis, iritis, skin lesions and hepatic compli­
cations may occur.
Despite recent advances and the introduction of new drugs, there is still no 
cure for CD. Corticosteroids are still the most commonly used drugs for the 
treatment of active CD, however, recent studies indicate that they are of no 
benefit in maintaining the remission (37). 6-Mercaptopurine and azathioprine 
have been shown to be beneficial in reducing corticosteroid dependence, espe­
cially in patients with colonic disease and internal fistulas (38-40). Sulfasala­
zine and newer 5-ASA preparations appear to be beneficial in patients with mild 
to moderate CD, especially when the large bowel is involved (41, 42). Metro­
nidazole has been recommended for the treatment of perianal Crohn’s disease 
(43, 44). A novel class of therapeutic agents is emerging from the combined 
unravelling of the mechanisms, leading to inflammatory lesions and progressing 
in molecular engineering. Of which the anti-tumour necrosis factor (TNF)-a 
monoclonal antibodies have already showed definite activity against chronic 
active CD in controlled trials (45, 46) and being since late 1998 used in patients 
with fistulae or severe steroid-resistant CD.
The majority of patients with CD will sooner or later require surgical 
removal of the diseased bowel with the principal surgical indications being 
internal fistulization with abscess and small or large bowel obstruction (47). 
Surgery does not cure CD and reoperation rates are as high as 50% for all the 
sites of the disease and even higher for fistulous or perianal disease (48). The 
data about the risk of colonic cancer are still conflicting. In the four studies (49- 
52) the risk for cancer was not different from the expected compared to the 
background population. Two studies (53, 54), however, reported a significantly 
increased risk of colonic cancer.
Four population-based studies have been published to date mortality in CD 
(49, 51, 55-56). Ekbom et al. (56) showed modest excess in mortality, whereas 
the other studies did not find any significant difference in mortality in CD 
compared to the expected mortality of the background population. However, 
Munkholm et al. (51), analysing subgroups of patients, found a significantly 
increased mortality in patients diagnosed at the age of 20-29 within the first 
5 years of the disease, and in a subgroup of patients with extensive both ileal
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and jejunal small bowel disease. Many studies have pointed to CD as becoming 
progressively more dangerous with the duration of the disease (49, 51, 57).
2.3. Autoantibodies and autoantigens in patients 
with inflammatory bowel disease
2.3.1. Antineutrophil cytoplasmic antibodies
Antibodies to a variety of autoantigens have been sought as evidence for auto­
immune mechanisms in patients with IBD.
Antineutrophil cytoplasmic antibodies (ANCA) were first described in a 
small group of patients with glomerulonephritis (58). In 1985 it was shown that 
the antibodies directed against cytoplasmic components of neutrophils occur in 
Wegener’s granulomatosis and correlate directly with the disease course and 
pathogenesis (59, 60). The antibodies, when detected by indirect immunofluore­
scence (IIF) on ethanol-fixed neutrophils, produce a characteristic cytoplasmic 
fluorescence pattern (cANCA). The antigen recognised by cANCA proved to be 
a 29-kd serine protease from myeloid azurophilic granules, known as proteinase-3 
(61, 62), During the routine screening of sera for the presence of ANCA, it 
became apparent that some sera produce a perinuclear to nuclear fluorescence 
pattern (pANCA) clearly different from the cANCA pattern and often directed 
against myeloperoxidase, another constituent of azurophilic granules (63).
More recently, ANCA have been reported to be present in 40-80% of the 
patients with UC and in 10-40% of the patients with CD (64-70). These ANCA 
usually produce an accentuated perinuclear (“atypical”) staining pattern on 
ethanol-fixed neutrophils (71). The target antigens in IBD have not been identi­
fied fully. Various target antigens have been described, of which lactoferrin (66, 
72) and bactericidal/permeability-increasing protein (BPI) (69, 73) are presently 
most prominent. Cathepsin G (74-76), lysozyme (77, 78), and p-glucuronidase 
(79) have also been reported as target antigens, although these results were not 
confirmed by others (66, 80). Recently, reactivity against catalase and a-enolase 
was observed by Roozendaal et a l (70). Several nuclear non-granulocyte-spe­
cific antigens have also been found to be recognised by ANCA positive serum 
samples from patients with UC (81). None of these antigens has been conclusi­
vely shown to be entirely responsible for the pANCA activity.
Certain aspects of the heterogeneity of the disease, particularly activity and 
extent at the precise time of venesection, are assessed in several studies. In most 
of the studies of UC the prevalence and titre of ANCA do not correlate with the 
disease activity or extent (64, 65, 69, 82), although some studies have suggested 
that pANCA may be associated with a more aggressive or more severe UC (83- 
85). Aitola and colleagues (86) have demonstrated reduction in the ANCA pre­
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valence and ANCA titre, judged by immunofluorescence, in patients with UC 
who had undergone proctocolectomy. Subsequently, Lindgren et a l (85) have 
reported on 137 patients with UC, the majority in long term remission, that only 
9% of the patients had circulating ANCA detectable. In CD, presence of 
pANCA seems to represent a distinct subpopulation of the patients who exhibit 
UC-like features (87, 88).
A related finding is that ANCA have been found in 15-20% of healthy 
unaffected relatives of the patients with UC (89, 90) and that it may be a marker 
of genetic susceptibility to UC. In addition to that, there is evidence to suggest 
that ANCA may be a marker of genetic heterogeneity within UC, because the 
linkage of HLA-DRB 1*1502 alleles with ANCA-positive UC but not with 
ANCA-negative UC has been described (91). Also a different distribution of 
ICAM-1 alleles in ANCA-positive and ANCA-negative subgroups of IBD pa­
tients has been reported (92). Although results vary depending on the patient 
population because a significant difference in HLA-DRB 1*1502 typing preva­
lence between ANCA-positive or -negative UC was not shown in separate 
studies from Pittsburgh (93) and Oxford (94). Recently, Satsangi et al (88) 
have provided further evidence that HLA genes are involved in determing 
ANCA status. In UC HLA-DRB 1*0301-DQB1 *0201/TNF2 (HLA-DR3- 
DQ2/TNF2-positive patients) haplotype was associated with high frequency of 
ANCA in patients’ serum, but again, in this population of UC, ANCA was not 
associated with HLA-DRB 1*15 or HLA-DRB 1*04 (serologically DR2 and 
DR4, respectively).
Although clearly pertinent to the present discussion, disease heterogeneity 
and ethnic differences alone would not explain the great discrepancies between 
the results of the many recent series in which ANCA prevalence has been 
measured in patients with UC and CD. Methodological differences may also be 
relevant. At present there is no consensus as to the “correct” assay for ANCA in 
UC. The techniques of alkaline phosphatase staining (95), immunofluorescence 
(67), and enzyme-linked immunosorbent assay (ELISA) (64) are all used in 
different centres. Differences in techniques also involve fixation (66) and dilu­
tion of serum. These are all likely to contribute to the present uncertainties.
The pathogenetic role of pANCA in the mucosal inflammation of IBD con­
tinues to be controversial. Supplementary evidence that inflammatory cells of 
the large bowel are important in ANCA production has recently been provided 
(96). These authors have been able to demonstrate spontaneous production of 
ANCA by the cells of the lamina propria of the colon of patients with UC. 
Spontaneous production was not demonstrated either by peripheral blood cells 
or by mesenteric lymph node cells. Although, the absence of pANCA in a 
significant fraction of patients with UC and the fact that pANCA can be found 
in some healthy individuals, indicates that they probably do not play a central 
role in the pathogenesis of UC, but may be indicative of an underlying immune 
disturbance (97, 98). In summary, humoral autoimmune phenomena are com­
mon in IBD, but their relevance to disease pathogenesis needs clarification.
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2.3.2. Other autoantibodies including antinuclear antibodies
Circulating antibodies to colonic epithelial cells were first described in the sera 
of the patients with UC over thirty years ago (99). Since then there have been 
many reports on this subject, and the antibody has been further characterised as 
an immunoglobulin of the IgGj subclass binding to a 40 kDa protein expressed 
by colonic epithelium, that is significantly more often found in UC than CD 
(100). Because of the apparently restricted localisation of the 40 kDa antigen to 
the epithelium of the colon, skin, and biliary tract, it has been proposed that 
there may be a colonic autoantigen in UC, which would also explain some of 
the extraintestinal disorders associated with UC (101). Most recently, the 40 
kDa antigen has been purified by Das et al (102) and shown to be related to 
tropomyosin, an actin-binding cytoskeletal protein known to be localised in the 
apical cytoplasm and brush border of colonic enterocytes. There is evidence that 
tropomyosin-related antigens possess epitopes that may cross-react with bac­
terial proteins (103). Such cross-reactivity with colonic bacterial antigens could 
potentially induce a state of chronic immunopathology, characterised by im­
mune complex deposition and leading to the activation of subepithelial macro­
phages through their Fc receptors. Whether these observations are simply 
epiphenomenal or whether colonic antibodies are really involved in the causa­
tion of UC remains to be established.
Other types of autoantibodies have been found to occur in IBD as, for 
example, antinuclear antibodies (ANA), smooth muscle antibodies (SMA), 
heat-shock protein antibodies, and antibodies against cytoskeletal proteins other 
than tropomyosin (104-107). Of which ANA and autoantigens targeted by 
ANA have revealed the most interest as valuable markers for the differential 
diagnosis in several systemic autoimmune diseases (108). Antibodies to the 
extractable nuclear antigens Sm (Smith), RNP, SS-A (Ro), SS-B (La), Scl-70 
and Jo-1 have been described in few patients with IBD (109,110).
There are isolated reports of autoantibodies to various components present in 
the intestinal wall, including intestinal, brush-border endothelial cells (111), and 
a trypsin-sensitive pancreatic antigen (112). However, none of them has been 
found to represent a specific marker for UC or CD and the mechanism of induc­
tion of these antibodies, and therefore the role in the pathogenesis of IBD re­
mains obscure. Not all antibodies lack specificity. A novel antierythrocyte auto­
antibody appears to have some specificity for CD (113). Antibodies to oligo- 
mannosidic epitopes of the yeast Saccharomyces cerevisiae (ASCA) are 
increased in patients with CD but not in UC (114-116). A recent study by 
Quinton et a l (116) showed that the combined use of ASCA and pANCA could 
differentiate CD from UC and other colitides.
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2.4. Extraintestinal manifestations of inflammatory bowel 
disease and associated diseases in patients with 
inflammatory bowel disease
IBD is associated with a variety of extraintestinal manifestations that may 
produce greater morbidity than the underlying intestinal disorder and may even 
be the initial presenting symptoms of IBD (117). About 30% of the patients 
with IBD have at least one extraintestinal manifestation. Extraintestinal mani­
festations may be divided into three categories (118), including (a) the 
complications directly related to IBD activity which usually respond to the the­
rapy directed against bowel disease: peripheral arthritis, episcleritis, aphthous 
stomatitis,, erythema nodosum, and pyoderma gangrenosum; (b) the disorders 
associated with IBD but running an independent course: ankylosing spondylitis, 
sacroiliitis, primary slerosing cholangitis; (c) the complications that relate 
directly to the disrupted bowel physiology: kindey stones, gallstones, amy­
loidosis, osteoporosis.
The pathogenic factors responsible for extraintestinal manifestations remain 
unclear. Some systemic disorders may be of immunologic origin and are likely 
related to the pathophysiology of the intestinal disease; others may be the 
sequelae of intestinal bacterial overgrowth or iatrogenic complications of the 
therapy used to control bowel inflammation (117).
A possible association between autoimmunity and UC was initially sug­
gested by the case reports of the associations between UC and thyroid disease 
(119), pernicious anaemia (120), systemic lupus erythematosus (121), and auto­
immune haemolytic anaemia (122). These observations were confirmed by 
Snook et al. (123), who demonstrated that the prevalence of a specified group of 
autoimmune disorders is three times greater than expected in subjects with UC; 
no association was found for CD. Monsen et al. (22), in a population-based 
study of 1274 patients with UC, determining the prevalence of extracolonic 
diagnosis, found that patients with extracolonic manifestations could be divided 
into two groups: activity-related and of autoimmune type. The overall prevalen­
ce of extracolonic diagnosis was 21%: 68 (25%) of these 271 patients with 
extracolonic diagnosis had more than one extracolonic diagnosis. Coexistence 
of several autoimmune diagnoses in patients with UC was common. The most 
common combinations were UC, Graves’ disease (thyrotoxicosis), and spondy­
litis; UC, Graves’ disease, and coeliac disease; UC, Graves’ disease, and pri­
mary sclerosing cholangitis; UC, psoriasis, and chronic active hepatitis (22).
2 ,4.1. Associations of ulcerative colitis and coeliac disease
Coeliac disease is an immunologically mediated disorder caused by lifelong 
intolerance of the small-bowel mucosa to dietary cereals, mainly wheat, rye,
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barley and oats (124). Ingestion of these cereal proteins results in villous 
atrophy, with crypt hyperplasia of the small-bowel mucosa, which recovers on a 
gluten-free diet. Coeliac disease may first develop either in childhood or in 
adult life with the clinical picture being very variable. Typical complaints are 
weight loss, fatigue, weakness and diarrhoea (125). In recent years it has be­
come apparent that the patients may completely lack any of the symptoms de­
scribed before and, therefore, the term “silent coeliac disease” has been intro­
duced (126). Clinically silent coeliac disease is increasingly being recognised 
(127). Even among these patients it is desirable to detect coeliac disease, as 
treatment with a gluten-free diet can prevent later manifest symptoms of malab­
sorption and even avert the potential development of malignant diseases (128). 
Diseases frequently occurring concomitantly with coeliac disease constitute 
such a risk group of which insulin dependent diabetes mellitus, Sjogren’s synd­
rome, and thyroid disease are the most frequent associations (12).
The first association of coeliac disease and UC was reported by Salem and 
Truelove over 30 years ago (13). Since then several other authors have de­
scribed the association of coeliac disease and UC (123, 129-136), as well. Most 
of the reports are simply case reports and, therefore, the clinical significance of 
this association is not yet established.
A conclusive diagnosis of coeliac disease is based on the demonstration of 
villous atrophy and crypt hyperplasia in small-bowel biopsy specimens (137, 
138). As endoscopy and the small-bowel biopsy are invasive procedures, they 
cannot be considered feasible for screening patients for coeliac disease, and 
therefore the desire for and the efforts to find suitable screening methods for 
replacement of the small-bowel biopsy, or for selecting patients who should 
further undergo small-bowel biopsy, have been great. Most suitable for the pa­
tients who might have silent coeliac disease are serologic tests. Three types of 
antibodies — antigliadin antibodies (AGA), antireticulin antibodies (ARA), and 
antiendomysium (AEM) antibodies have been extensively investigated and 
suggested as screening tests for coeliac disease (139-141).
The tests most widely used measure AGA of IgG and IgA-class, most com­
monly utilising an ELISA. Reports differ on the reliability of the tests (142), af­
fected by the age of the patients and on the activity of the disease. Gliadin anti­
body tests are excellent in young children with active disease. The IgA-class 
antibody test has a sensitivity of approaching 100% (except in patients with 
IgA-deficiency) and its specificity is also high. The IgG-class test also has high 
sensitivity but lower specificity (143). In older children and adults, especially 
when they are clinically silent, results are less reliable. Sensitivity is only 50- 
80%. The reduction of the cut-off level for positivity leads to many false-posi­
tive results (144). The IgG-class test may be more sensitive and IgA-class more 
specific. These results were also confirmed by O. Uibo et al. (145), studying the 
prevalence of coeliac disease with screening tests among 1434 children and 
1461 adults. According to their results the AGA test could be used for coeliac 
disease screening in childhood (of the 44 IgA AGA positive children in 33
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coeliac disease was confirmed by small bowel biopsy); but in the case of adults 
there are some limitations (of the 52 IgA AGA positive persons from Karksi- 
Nuia population in 49 normal small bowel mucosa was revealed, 3 refused the 
biopsy). The significance of positive AGA in patients with normal small-bowel 
mucosa is obscure.
The determination of antibodies against reticulin has been reviewed quite 
recently. The detection of Rl-type ARA by the IIF method, using rat kidney as 
an antigen, has been shown to be very sensitive and also specific for coeliac 
disease (146, 147). Furthermore, a positive ARA test is highly suggestive of 
latent coeliac disease in patients with normal mucosal architecture, and there­
fore these patients should not be lost to follow-up (148). The results of using 
this test in different centres are, however, extremely confusing, presumably due 
to differences in technical details (143).
Chorzelski et a l (149) described a new antibody directed against the memb­
rane of smooth muscle bundles of primates. This endomysial antibody was 
present in patients with dermatitis herpetiformis and coeliac disease and has 
been found to have greater sensitivity and specificity than AGA in diagnosing 
coeliac disease (141, 150-153), and in the case of general screening AEM eva­
luation has also been used as the final step before intestinal biopsy (154, 155). 
These IgA-type AEM are detected by performing IIF on muscular sections of 
monkey oesophagus or umbilical cord (150, 152). Recently, tissue transgluta­
minase was identified as the autoantigen to endomysial autoantibody (156).
2.5. Genetic aspects of inflammatory bowel disease
Many studies have demonstrated increased prevalence of inflammatory bowel 
disease among the relatives of the patients with UC and CD (157, 158). Consis­
tent trends are noticeable. First-degree relatives are at the greatest risk, parti­
cularly siblings, but more distant relatives also display increased disease pre­
valence. A positive family history is more common in the relatives of the pa­
tients with CD than UC.
In Oxford study (159) information was obtained from 433 adult patients 
with CD using postal questionnaire, review of case notes and personal inter­
views. In 78 families (18%), at least one first- or second-degree relative also 
had IBD. Siblings were most commonly affected. CD was more common than 
UC in the affected siblings. Assuming population prevalence of 100 per
100,000 for UC and 70 per 100,000 for CD the relative risks in siblings of the 
patients with CD, calculated from these data, were 16.6 for UC, 36.5 for CD 
and 24.7 for IBD, respectively.
These data complement the results of the Swedish twin study (160) which 
strongly implicated genetic susceptibility in the pathogenesis of UC and CD.
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There is a significant increase in the concordance of IBD in monozygotic twins 
compared to that in dizygotic twins, especially with CD.
In addition, many groups have collected the clinical data from multiply 
affected families and studied the extent of disease heterogeneity and the 
influence of genetic and environmental factors on disease behaviour. The data 
from the studies in the U.S.A. (161) and France (162) have demonstrated a 
marked concordance in the members of the multiply affected families with CD 
for disease extent and behaviour. In a recently published Oxford study (163) of 
over 250 multiply affected families in affected parent-child pairs, parent and 
child were concordant for disease type in 75.3%, for extent in 63.6%, extra­
intestinal manifestations in 70.1%, and smoking history in 85%. Of particular 
note in this study was the fact that the median age at the diagnosis in parents 
was significantly higher than in offsprings. In a study from Polito et a l (161) 
the children were not only significantly younger at the age of the onset of the 
disease, but were generally also suffering from a more extensive disease.
The explanation for this observation is uncertain. Polito et a l (161) have 
suggested that the observed age differences may represent genetic anticipation. 
This phenomenon, the tendency for successive generations to develop a disease 
of increasing severity and earlier onset, has been observed in monogenic dis­
orders, particularly in neurodegenerative diseases. The molecular basis for this 
effect involves the progressive amplification of unstable triplet repeats of DNA
(164). Whether this explanation is pertinent to complex disorders such as IBD, 
or whether the observations reflect ascertainment bias or any other variable
(165), is still uncertain.
Although genetic predisposition seems relatively more important in CD than 
UC, no simple Mendelian mode of inheritance is pertinent to either condition. It 
is most likely that the IBD represent a heterogeneous group of the related poly­
genic disorders, sharing some but not all susceptibility loci (166). Clinical pre­
sentation may depend on the interaction between different genes, and also on 
allelic variation in individual genes.
2.5.1. Genes involved in susceptibility to inflammatory bowel disease
The genes of the human major histocompatibility complex (MHC), which plays 
a central role in the immune response, have gained a lot of interest. Although, 
the data concerning the importance of these genes in UC and CD have, until 
recently, remained confusing and inconsistent, except for those small subgroups 
of patients with concomitant ankylosing spondylitis (associated with HLA-B27) 
or primary sclerosing cholangitis (associated with HLA-DR3-DQ2 or HLA- 
DR2) (158). The results have been more consistent with UC than with CD. 
Allelic associations have been reported between HLA-DR2 (HLA-DRB 1*1502) 
and UC in Japanese (167), Jewish (168) and recently in Dutch (169) patients. 
However, this has not been confirmed in British (94) and American (93)
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patients. In CD, in two recent studies from Germany (170) and France (171), a 
positive association with the HLA-DRB 1*07 allele, and a negative association 
with the HLA-DRB 1*03 allele was observed. In sharp contrast, no evidence 
that class II genes contribute to CD susceptibility and disease phenotype was 
reported in a British study (94). These observations show the importance of 
ethnicity in studying the genetics of IBD.
A further controversy lies on the relationship between HLA genotype and 
disease behaviour in UC. Satsangi et al. (94) not only showed the linkage 
between UC and HLA-DRB 1 genes in a group of affected sibling pairs but, in a 
large association study (175 UC patients, 173 CD patients), found a number of 
interesting associations between specific Class II genes and clinical phenotype. 
Thus, the HLA-DR3-DQ2 (HLA-DRB 1*0301-DQB 1*0201) haplotype was 
associated with extensive disease and was rarely present in distal colitis, espe­
cially in females. A further association was with the rare HLA-DR103 (HLA- 
DRB 1*0103) allele which had a frequency of 3% in the control population and 
a frequency of 8.6% in UC. Further analysis showed that the frequency rose to 
11 % in patients with extensive disease or severe disease requiring surgery. This 
latter hypothesis was then tested in a separate group of 107 patients with UC 
that had undergone proctocolectomy and an ileo-anal pouch anastomosis (172). 
The frequency of HLA-DR103 was again 11.8% but rose to 24% in patients 
who had extraintestinal manifestations (mouth ulcers, arthritis, erythema nodo­
sum, uveitis).
Cytokines have an important role in the initiation and amplification of the 
inflammatory response in the mucosa in IBD (3), and the genes involved in the 
regulation of the immune response or maintenance of mucosal integrity repre­
sent candidate genes in IBD. Of particular present interest are the genes en­
coding the naturally occurring antagonist to interleukin-1, interleukin-1 receptor 
antagonist (EL-IRA), and the gene encoding the pro-inflammatory cytokine 
tumour necrosis factor-a (TNFa). Nevertheless, the results of the studies 
investigating cytokine gene polymorphisms in patients with UC or CD have 
been very conflicting. Mansfield et al. (173) initially reported that a poly­
morphism in intron 2 of the IL-1RA gene on chromosome 2 was associated with 
UC, especially with extensive colitis. This observation has been confirmed in 
some of the studies only, thus, the association with UC is, at best, weak (174). 
Furthermore, the significance of the observation is not clear, since the poly­
morphism is in a non-coding part of the gene.
A similar confusion arises with regard to TNFa polymorphisms. The studies 
from Oxford (175) have not shown significant associations with bi-allelic 
polymorphisms in the promoter region of the gene, but a significant association 
between CD and the TNFct-308 allele 2 was found in the Dutch series (176). 
Positive effects in the treatment of the CD patients with anti-TNFa monoclonal 
antibodies also support the presumption that TNF is involved in the patho­
genesis of IBD, but the detailed mechanism still remains unclear (46,177).
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Cell surface adhesion molecules represent a large family of the molecules 
essential for cell communication, activation, and homing. As IBD is characte­
rised by the infiltration of the inflammatory cells derived from the circulation 
including monocytes, lymphocytes, and neutrophils, a fundamental role of 
adhesion molecules is expected. Aberrant expression of cell adhesion molecules 
in the areas of inflammation is confirmed by several reports. In active IBD, mu­
cosal mononuclear phagocytes show a dramatic increase in expression of inter­
cellular adhesion molecule 1 (ICAM-1) (178). In addition, increased circulating 
concentrations of the vascular cell adhesion molecule 1 (VCAM-1) and E- 
selectin are also found (179,180). Recently, a different distribution of soluble 1 
(ICAM-1) alleles in subgroups of IBD patients, stratified by ANCA status, has 
been reported (92).
However, these and other candidate genes remain under evaluation and re­
quire replication in independent data sets before final conclusions are possible.
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3. AIMS OF THE STUDY
The overall aim of the present studies was to investigate the presence and distri­
bution of different antibodies and genetic markers in the patients with IBD to 
improve our current understanding of their role in the aetiology and pathogene­
sis of IBD.
The specific objectives were:
1. to determine the prevalence and clinical value of ANCA in the patients with 
IBD (I, II);
2. to analyse the pattern of ANCA by IIF and to characterise the antigen speci­
ficity of ANCA by ELISA, using myeloperoxidase, proteinase-3, lactoferrin 
and cathepsin G as antigens (I);
3. to determine the prevalence and clinical value of several non-organ-specific 
antibodies in the patients with IBD and to analyse ANA containing sera by 
ELISA to the extractable nuclear antigens Sm (Smith), RNP, SS-A (Ro), SS- 
B (La), Scl-70 and Jo-1 (II);
4. to examine the frequency of AGA, ARA and AEM in the patients with UC 
and to evaluate the correlations between these antibodies and various clinical 
features in the patients with UC (HI);
5. to investigate the polymorphisms of HLA-DR and -DQ, tumour necrosis 
factor (TNF), E-selectin, L-selectin and intercellular adhesion molecule 1 
(ICAM-1) in the patients with IBD and to determine relationships between 
these markers and ANCA status (IV).
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4. PART I: THE FREQUENCY AND CLINICAL VALUE 
OF DIFFERENT AUTOANTIBODIES IN PATIENTS 
WITH IBD (PAPERS I, II)
4.1. Patients
All the serum samples were obtained from the patients with UC or CD attending 
the Department of Internal Medicine, the University of Tartu, or the University 
Outpatient Department. In Paper I, 59 patients with UC and 17 with CD and in 
Paper II, 77 patients with UC and 31 with CD were studied. For UC, the diag­
nostic criteria were based on a history of bloody stools, typical colonoscopy 
findings, and morphological changes in biopsy specimens. The extent of colitis 
in the patients with UC was evaluated with colonoscopy and, in some cases, 
with barium enemas. Proctitis refers to mucosal inflammation found in the 
rectum only, the disease extending proximally up to the mid-transverse colon is 
classified as left-sided colitis and the disease engaging (extension beyond mid- 
transverse colon) the whole of the colon and rectum refers to extensive colitis. 
For CD, the diagnostic criteria worked out by Lennard-Jones were followed 
(181). Disease localisation was evaluated by small-bowel roentgenograms, ba­
rium enemas and colonoscopy. Disease location was defined: ileum (disease li­
mited to the small bowel), colon (any colonic location between the caecum and 
rectum with no small bowel or upper gastrointestinal involvement), ileocolon 
(disease of the terminal ileum and any location between the caecum and rectum). 
The clinical characteristics of the studied patients are shown in Table 1.
Table 1. Clinical characteristics of the patients with inflammatory bowel disease (IBD) 
at the time of serum sampling.
Paper I Paper II
Diagnosis UC CD UC CD
(n=59) (n=17) (n=77) (n=31)
Male/Female 28/31 13/4 40/37 23/8
Mean age (years) 44 27 43 36
Disease extent
Proctitis, n (%) 25 (42) 31 (40)
Left-sided, n (%) 13 (22) 23 (30)
Extensive, n (%) 21 (36) 23 (30)
Disease localisation
Ileum, n (%) 3(18) 7(23)
Colon, n (%) 6(35) 9(29)
Ileum and colon, n (%) 8(47) 15 (48)
Duration of disease
<5 years, n (%) 21 (36) 13 (76)
>5 years, n (%) 38 (64) 4 (24)
UC -  ulcerative colitis; CD -  Crohn’s disease
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The control groups consisted of the patients with the irritable bowel syndrome 
(IBS) and healthy persons with no history of gastrointestinal or chronic disease. 
In paper 125 patients with IBS (12 male, 13 female; mean age 38 years) and 86 
healthy persons (31 male, 55 female; mean age 39 years); in paper I I 32 patients 
with IBS (16 male, 16 female; mean age 38 years) and 76 healthy persons (30 
male, 46 female; mean age 40 years) served as controls. The study was ap­
proved by the Ethics Committee of the University of Tartu.
4.2. Methods
10 ml of venous blood was taken from each subject and stored at -20° C until 
analysed. All tests were performed at the Department of Immunology, the Uni­
versity of Tartu, continuously controlled by UKEQAS (Sheffield, UK).
4.2.1. Indirect immunofluorescence assay (IIF)
The separation of peripheral blood neutrophils and the detection of ANCA by 
IIF were performed, with minor modifications, according to the method de­
scribed by Wiik (182).
Briefly, neutrophils were separated from the peripheral blood of a healthy 
volunteer by Ficoll-Hypaque centrifugation and dextran sedimentation. The 
buoyant neutrophils were recovered and washed. Cellular suspensions were 
smeared on slides and fixed in 96% ethanol for 5 minutes, dried at room tempe­
rature and stored at -20°C until the time of the assay, but not more than for two 
weeks. The slides were incubated with coded patients or control sera (dilution 
1:20) and stained with rabbit antihuman IgG-fluorescein isothiocyanate (FTTC) 
conjugate (Dakopatts, Glostrup, Denmark). The slides were evaluated by fluore­
scence microscopy. Positive and negative controls were included for all assays. 
The serum samples giving a typical perinuclear (pANCA) or cytoplasmic 
(cANCA) staining reaction with the neutrophils were regarded as positive. 
pANCA are present when reactivity is seen only with the neutrophils and the 
monocytes or when present in a much higher titre than on, for example, 
lymphocytes. To ensure that ANCA in IBD indeed recognise cytoplasmic anti­
gens, all sera for the presence of ANA on rat liver slices were screened.
IgG-type antinuclear (ANA), antimitochondrial (AMA), smooth muscle 
(SMA), antireticulin (ARA), liver/kidney microsomal (LKMA), parietal cell 
(PCA) and thyroid microsomal (TMA) antibodies were tested by DF on unfixed
4 |im cryostat sections from a composite block of a mouse stomach and rat 
kidney and liver, as well as from a hyperplastic human (blood group 0) thyroid 
gland (183). Coded patients or control sera were diluted at 1:10 and 1:100 in
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phosphate-buffered saline (PBS) and tested on the sections using rabbit anti­
human IgG fluoresceinisothiocyanate (FITC) conjugate (Dako, Copenhagen, 
Denmark) at dilution 1:80 as a secondary antibody. All the sera containing 
ANA were further analysed on ethanol-fixed Hep2 (Immuno Concepts, Sacra­
mento, USA) cells at the dilution of 1:40 in PBS.
4.2.2. Enzyme-linked immunosorbent assay (ELISA)
Commercially available kits based on enzyme immunoassay were used for the 
analysis of myeloperoxidase and proteinase-3 antibodies of IgG isotype (Wies- 
lab AB, Lund, Sweden). Both kits were used according to the manufacturer’s 
instructions. A serum dilution of 1:80 was used in both assays. Alkaline 
phosphatase-labeled anti-human immunoglobulin G was used as a second anti­
body. The reaction was visualised using p-nitrophenyl phosphate as a substrate, 
and read at 405 nm. Values exceeding the borderline (20 EU) were regarded as 
positive. The anti-lactoferrin and anti-cathepsin G ELISAs were performed as 
originally described (182, 184). Briefly, ELISA microtiter plates (Nunc, Ros- 
kilde, Denmark) were coated overnight at 4°C, with 5 jxg/ml human neutrophil 
lactoferrin (Sigma, St. Louis, Mo., USA), or 0.5 Mg/ml cathepsin G (Calbio- 
chem, La Jolla, Calif., USA) in carbonate buffer (pH 9.6), and in 50 mM 
sodium acetate with 150 mM NaCl (pH 5.5), respectively. Plates were saturated 
with 1% bovine serum albumin in PBS (PBS/BSA) or with 5% swine serum 
albumin in PBS (PBS/SSA), respectively. The controls and serum samples were 
diluted at 1:100 in PBS/BSA 1 %/Tween 0.1% and incubated for one hour at 
room temperature. The bound IgG was detected using alkaline phosphatase-con­
jugated anti-human IgG (Dako, Glostrup, Denmark), followed by p-nitrophenyl 
phosphate as a substrate. Sera from 40 healthy persons were used as references 
to establish a base-line absorbance value and defined as two standard deviations 
above the mean value.
ANA containing sera were analysed by ELISA for secondary confirmatory 
testing of IgG antibodies to the extractable nuclear antigens Sm (Smith), RNP, 
SS-A (Ro), SS-B (La), Scl-70 and Jo-1 using the Immuno Concepts RELISA 
ENA multiparameter test system (Immuno Concepts, Sacramento, CA, USA).
4.2.3. Statistical analysis
The chi-square test was used to analyse differences between the groups, p<0.05 
was considered to be significant. Comparing small numbers the Fisher’s exact 
test was performed.
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4.3. Results
4.3.1. Antineutrophil cytoplasmic antibodies in patients with 
inflammatory bowel disease
In paper I IgG ANCA were detected by IIF on ethanol-fixed granulocytes in 29 
of the 59 (49%) patients with UC and in 4 of the 17 (24%) patients with CD 
(p=0.06). In the control group 4 of the 111 (4%) serum samples were positive to 
ANCA, 1 sera of the 25 patients with the irritable bowel syndrome, and 3 of the 
86 healthy subjects sera (pcO.OOl for UC compared with controls; p<0.01 for 
CD compared with controls). In paper II IgG ANCA were detected in 45 of the 
77 (58%) patients with UC and in 6 of the 31 (19%) patients with CD (p<0.05 
with Yates’ correction). In the control group 2 of the 108 (2%) persons 
(1 patient with the irritable bowel syndrome, and 1 healthy person) were posi­
tive to ANCA (pcO.OOl with Yates’ correction for UC compared with the 
controls and for CD compared with the controls).
The predominant ANCA staining pattern seen by IIF in IBD is perinuclear 
(pANCA). The cytoplasmic staining (cANCA) was revealed in 6 patients with 
UC and 1 patient with CD in paper I and in 5 patients with UC and 1 patient 
with CD in paper II. One patient with UC had both, perinuclear and cytoplasmic 
staining (paper I, II). In the control groups only 3 of the 111 sera showed a weak 
perinuclear staining and 1 sera cytoplasmic staining in paper I, and in paper II 
only 2 of the 108 sera showed a weak perinuclear staining. The distribution of 
ANCA in the patients’ and controls’ sera is shown in Table 2.
Table 2. Distribution of the antineutrophil cytoplasmic antibodies (ANCA) in patients’ 
and controls’ sera detected by indirect immunofluorescence.
IIF ANCA- Immunofluorescence staining 
N positive ____________ pattern_________
n(%) pANCA cANCA p+cANCA
Paper I UC 59 29 (49) 22 6 1
CD 17 4(24) 3 1 0
Controls 111 4(4) 3 1 0
Paper II UC 77 45 (58) 39 5 1
CD 31 6(19) 5 1 0
Controls 108 2(2) 2 0 0
UC -  ulcerative colitis; CD -  Crohn’s disease
No correlation between the presence of ANCA and the extent or duration of 
IBD was found (Table 3).
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Table 3. Relationship between the clinical features of inflammatory bowel disease (IBD) 
and the presence of antineutrophil cytoplasmic antibodies (ANCA).
Paper I Paper II
ANCA positive patients/total number of patients
UC CD UC CD
29/59 4/17 45/77 6/31
Disease extent
Proctitis 11/25 17/31
Left-sided 7/13 12/23
Extensive 11/21 16/23
Disease localisation
Ileum 0/3 0/7
Colon 0/6 1/9
Ileum and colon 4/8 5/15
Disease duration
<5 years 14/21 3/13
> years 15/38 1/4
UC — ulcerative colitis; CD — Crohn’s disease
To ensure that ANCA in IBD indeed recognise cytoplasmic antigens, all the 
sera for the presence of ANA on rat liver slices were screened. In paper I ANA 
(1:10) were detected in 5 UC patients and 1 patient with CD; all the patients 
were pANCA positive and without liver abnormalities. In the control group 1 
sera was ANA positive. All the 7 ANA positive sera were retested on the Hep2 
cell lines at the dilution of 1:40. Two female UC patients and one male CD 
patient were found to be ANA positive. ANA in all of them produced a homo­
geneous staining pattern of the nucleus. In paper II 8 out of the 45 pANCA 
positive UC patients had an additional nuclear staining on lymphocytes, in all 
cases confirmed to be due to ANA on the cryostat sections. In addition, 1 pa­
tient with CD showed a pure nuclear staining on both granulocytes and lympho­
cytes. This was shown to be due to the presence of ANA, by positive staining 
reactions on the cryostat sections.
To characterise the specificity of ANCA, sera were screened with ELISA 
using proteinase-3, myeloperoxidase, lactoferrin, and cathepsin G as antigens 
(paper I). Of the 59 UC and 17 CD sera, only 14 of the 76 (18%) sera were 
positive. The antibodies to proteinase-3 were detected in 5 UC and 1 CD sera, 
of which 3 UC and 1 CD sera had scored positive for cANCA. One UC serum 
scored positive for pANCA and 1 UC serum had both types of ANCA. The 
antibodies to myeloperoxidase were not detected. The anti-lactoferrin antibodies 
were detected in 6 UC and 1 CD patients’ sera, of which 3 UC and 1 CD sera 
were pANCA positive, 1 UC serum had both types of ANCA, and 2 were 
negative on IIF. The antibodies to cathepsin G were detected in 3 UC and 2 CD 
patients’ sera, of which 1 UC and 1 CD sera were pANCA positive, and 2 UC
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and 1 CD sera were negative on IIF (Table 4). Three patients with UC and 1 
with CD had positive ELISA for two different antigens.
Table 4. Number of the antineutrophil cytoplasmic antibodies (ANCA) positive sera 
detected by ELISA with different antigens (Paper I).
Antigen
Ulcerative colitis 
(n=59)
Crohn’s disease 
(n=17)
ELISA+ IIF+ ELISA+ HF+
Proteinase-3 5 5 1 1
Myeloperoxidase 0 0 0 0
Lactoferrin 6 4 1 1
Cathepsin G 3* 1 2 1
* Fifty-six sera from the patients with ulcerative colitis were studied.
4.3.2. Other autoantibodies in the patients with 
inflammatory bowel disease
IgG ANA, SMA, TMA or/and PCA were detected by IIF in 19 of the 77 (25%) 
patients with UC. Eight of the 31 (26%) patients with CD had ANA or SMA. 
There was no difference in the frequency of autoantibodies between UC and CD 
(p=1.0 with Yates’ correction). In the control group, 13 out of the 108 (12%) 
persons were positive for ANA, SMA, TMA or/and PCA (p<0.05 with Yates’ 
correction for UC compared with controls; p=0.1 with Yates’ correction for CD 
compared with controls).
Most of the UC and CD patients had these autoantibodies in low (1:10) 
titres. Only 4 patients with UC (2 with AIH and 2 females without liver abnor­
malities) and 1 male with CD (without liver abnormalities) had ANA at the 
serum dilution of 1:100, 1 female patient with UC had TMA and PCA at 1:100. 
In the control group 1 female had TMA and 1 male PCA in titre 1:100 positive. 
None of the 216 serum samples were positive for AMA, ARA or LKMA. The 
frequencies of different autoantibodies are summarised in Table 5.
All the 12 positive ANA sera were further analysed on ethanol-fixed HEp-2 
cell preparations at the dilution of 1:40. Three out of 12, i.e. 2 female UC 
patients (1 with AIH and the other without liver abnormalities) and 1 male CD 
patient (without liver abnormalities), all 1:100 positive on the cryostat sections, 
were also found to be positive on Hep-2 cells (homogeneous pattern).
Out of the 11 ANA positive sera (1 healthy person’s sera was not further 
available), screened by ELISA for Sm, RNP, SS-A, SS-B, Scl-70 and Jo-1 
antibodies, reactivity to the Scl-70 antigen was seen in a 23-year old woman 
with long-standing extensive colitis and concurrent AIH. The medical records 
of our patient were carefully revised, but no signs of systemic sclerosis were 
found.
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Table 5. Frequencies of ANA, SMA, TMA and PC A in patients’ and controls’ sera
detected by indirect immunofluorescence (Paper II).
Titres of No. of ANA, SMA, TMA or PCA positive patients
autoantibodies UC (n=77) CD (n=3I) Controls (n=108)
ANA 1:10 5 1 1
1:100 4 1 -
SMA 1:10 5 6 8
1:100 - - -
TMA 1:10 1 - -
1:100 1 - 1
PCA 1:10 2 - 2
1:100 1 - 1
Total 1:10 13 (17%) 7 (23%) 11 (10%)
1:100 6 (8%) 1 (3%) 2 (2%)
ANA — antinuclear antibodies; SMA — smooth muscle antibodies; PCA — parietal cell 
antibodies; UC — ulcerative colitis; CD — Crohn’s disease
4.4. Discussion
It is well accepted in rheumatology that ANA and ANCA have become useful 
tools not only for differential diagnosis but even for prognosis, early diagnosis 
and sometimes for monitoring disease activity. Disappointingly, in IBD most of 
the autoantibodies described lack sensitivity or specificity, and in this way, 
suggesting them to be of little pathogenic relevance. In recent years ANCA has 
been recognised in patients with IBD and have become a valuable laboratory aid 
in the diagnosis of IBD, although the antigen(s) responsible has not been iden­
tified yet.
The present studies showed that ANCA are often present in the ulcerative 
colitis patients in Estonia. ANCA were detected in 49-58% of the patients with 
UC and in 19-24% of the patients with CD (Paper I and Paper II). It has been 
suggested in the literature (185, 186) that ANCA may help differentiate UC 
from CD, as ANCA has been found in a low frequency in the patients with CD. 
The prevalence of ANCA in our patients with CD was rather high (24% and 
19% in Paper I and Paper II, respectively), showing its limited role in diffe­
rentiating the diseases. Therefore we do agree with the findings of Broekroelofs et 
al (83), showing ANCA to be of limited or no value in distinguishing Crohn’s 
disease from ulcerative colitis. At the same time, colonic involvement in ANCA 
positive patients with CD seems to be important as none of our CD patients with 
small bowel disease did have ANCA only. These results confirm the data 
described previously (64, 69, 88) and support the idea that pANCA positive CD 
patients may represent a distinct disease subgroup (87).
The predominant ANCA staining pattern observed in our studies was peri­
nuclear that is being also affirmed by other authors in the case of IBD. However, it
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is distinct from vasculitis-associated pANCA, and it is not generally reactive with 
myeloperoxidase (64, 67, 83). In contrast with cANCA, which have shown to 
serve a highly sensitive and specific marker for Wegener’s granulomatosis (59, 
187, 188), in IBD the pathogenetic role and clinical significance of pANCA is less 
favourably established. The problem is that ANCA are present only in 40-85% of 
the patients with UC (64-70), and most of the authors have failed to show neither 
the correlation between ANCA and disease activity nor ANCA and disease extent 
(64, 65, 69, 82), although some studies have suggested that pANCA may be as­
sociated with a more aggressive or more severe UC (83-85). No correlation be­
tween ANCA and the duration, or ANCA and the extent of IBD was found in our 
study.
The other problem is that test sera may contain other antibodies, including 
antinuclear antibodies which may result in a staining pattern not dissimilar to that 
of pANCA. Therefore, the screening of the sera with the non-specific staining 
patterns, and equivocally, ANCA positive for the presence of ANA, is useful until 
the antigen(s) responsible for ANCA are identified. And that is when it may be 
expected that the problems associated with the recognition of ANCA can be 
overcome. Fortunately, the number of IBD patients with concomitant ANA in our 
studies was not high and most of the patients had these antibodies in low titre 
(1:10) only. Therefore simultaneous screening of these sera for ANCA and ANA, 
using titration, is essential and this is how the problem in most of the cases can be 
solved.
Whereas the antigen specificity of ANCA in IBD is still uncertain, antibodies 
to several constituents of neutrophils including cathepsin G (74-76), lactoferrin 
(66,72), p-glucuronidase (79), and recently bactericidal/permeability-increasing 
protein (69,73) have been reported in some patients with IBD. None of these is 
being proved to be exclusively responsible for the pANCA activity. In the present 
study 18% of the serum samples were positive in the specific ELISA assays (Paper 
I). Though the immunofluorescence and ELISA results did not correspond in our 
study, we support the findings that other antigens than proteinase-3, myeloper­
oxidase, lactoferrin and cathepsin G can be the targets for ANCA in the patients 
with IBD and remain to be evaluated in further investigations.
We also studied the presence of ANA, AMA, SMA, ARA, LKMA, PCA and 
TMA by IIF. All ANA containing sera were further analysed by ELISA for 6 
different antibodies against extractable nuclear antigens. The ANA, SMA, TMA 
and PCA detected in the patients with IBD were in general of low titre and 
frequency. Although 25% of the patients with UC and 26% of the patients with 
CD compared to 12% of the controls had these antibodies; only 8% of the UC 
patients, 3% of the CD patients and 2% of the controls had them at the dilution 
of 1:100. In contrast, Dalekos et al. (109) in their study found ANA in 41 out of 
the 80 (51%) patients with UC. Although they used HEp-2 cells (positive ANA 
titre >1:80) for the detection of ANA, it seems to us that the differences in the 
prevalence of ANA can not be explained by technical differences only. Indeed, 
in our studies 2 out of the 5 patients with ANA in titre 1:100 had concomitant
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AIH. Therefore our results rather suggest that in our patients with IBD ANA in 
high titres are infrequently present. We suggest that different genetic and 
environmental backgrounds play role in the lower prevalence of ANA. Our 
results are also supported by Uibo et al. (189); comparing prevalence of diffe­
rent autoantibodies among young adults in Estonia and Sweden they found that 
the prevalence of ANA was significantly lower in Estonia (7% vs. 12%). Re­
activity to the Scl-70 antigen was seen in a patient with long-standing extensive 
colitis and concurrent AIH. The antibodies to DNA topoisomerase I, also 
known as Scl-70, are generally associated with diffuse cutaneous systemic 
sclerosis (190) and have even been shown to be present for months or years 
before the clinical expression of the disease (191). No signs of systemic scle­
rosis were found in our patient.
It has been suggested that autoimmune mechanisms are more likely to be 
involved in the pathogenesis of UC than that of CD (192). The higher pre­
valence of associated autoimmune diseases and different autoantibodies in the 
case of UC supports the idea. Our study confirms that ANCA are more often 
present in the patients with UC than in the patients with CD. In the case of other 
autoantibodies the significant difference between UC and CD could not have 
been revealed. A fundamental question is the true relevance of autoantibodies to 
UC in particular and IBD in general. pANCA have yet to be proven to alter the 
neutrophil function, although the recent demonstration of pANCA-producing B- 
cell clones in UC mucosa leaves the door open to alternate roles (96). A related 
question remains to be asked, how many other autoantibodies exist in IBD and 
what is the range of their specificity. Humoral autoimmune phenomena are 
common in IBD, but their relevance to disease pathogenesis needs clarification, 
particularly because the simple occurrence of autoantibodies no longer indicates 
a pathological condition, but it is part of normal immune homeostasis (193). 
Further investigations on the molecular structure and function of target auto­
antigens of ANCA and other autoantibodies are extremely valuable and may 
significantly contribute to our understanding of the cellular processes taking 
place in IBD.
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5. PART II: THE ASSOCIATIONS BETWEEN 
COELIAC DISEASE RELATED ANTIBODIES AND 
ULCERATIVE COLITIS (PAPER III)
5.1. Patients
A total of 103 persons were investigated in the present study. Fifty serum 
samples were obtained from the consecutive unselected patients with UC (25 
males, 25 females, from 14 to 75 years of age, mean age 43 years) attending the 
Department of Internal Medicine, the University of Tartu or the University 
Outpatient Department. The diagnosis of UC was based on the conventional 
criteria described earlier. The UC patients were classified according to disease 
extent, disease activity and disease duration at the time the blood sample was 
obtained. The extent of colitis was evaluated in 43 cases in colonoscopy and in 
7 cases in radiological investigation. Nineteen patients had proctitis, 12 left­
sided colitis, and 19 extensive colitis. Disease activity was assessed by the 
criteria of Truelove and Witts (28). UC was characterised as mild, moderate, or 
severe based on equal weighting of the following six factors: diarrhoea, fever, 
tachycardia, anaemia, erythrocyte sedimentation rate, and physical examination. 
Twenty-two of the 50 UC patients were in clinical remission, 10 had mild 
disease, 14 moderate disease, and 4, severe disease. Twenty-two of 50 patients 
with UC were treated with a combination of systemic or topical steroids and 
sulfasalazine or 5-ASA. The other patients received no medication or sulfa­
salazine or 5-ASA only. Finally, duration of disease was considered: 21 patients 
had been suffering from UC less than for 5 years and 29 patients 5 years or 
more.
The control group consisted of 53 individuals, age- and sex-matched with 
the UC group (24 males, 29 females, from 16 to 79 years of age, mean age 43 
years). Sixteen patients had the irritable bowel syndrome (DBS) (9 males, 7 fe­
males, from 16 to 62 years of age, mean age 40 years) and 37 were healthy indi­
viduals (15 males, 22 females, from 17 to 79 years of age, mean age 46 years) 
with no history of gastrointestinal or other chronic diseases. The study was 
approved by the Ethics Committee of the University of Tartu.
5.2. Methods
Ten ml of venous blood was taken from each subject and stored at -20°C until 
analysed for IgA- and IgG-type AGA, IgG-type ARA and IgA-type AEM. All 
tests were performed at the Department of Immunology, the University of 
Tartu, continuously controlled by UKEQAS (Sheffield, UK).
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5.2.1.1. Detection of the antireticulin antibodies
Rl-type ARA were detected using a standard IIF method (194) with rat kidney, 
liver and mouse stomach mounted into a composite block as antigen substrates, 
and fluorescein isothiocyanate (FITC)-conjugated rabbit antihuman IgG 
(DAKO A/S, Glostrup, Denmark) as the secondary antibody. The sera were 
investigated at the dilutions of 1:10 and 1:100 in PBS, and were considered 
ARA positive if the characteristic R1-staining pattern was found in antigen 
substrates under the fluorescence microscope (Jenalumar SH 50; VEB Carl 
Zeiss, Jena, Germany [with ocular x 6.3 and objective x 25 and x 50]). The 
specific pattern included staining of the fibres around the glomeruli and tubuli 
and around the blood vessels in the kidney section; staining of the nodular fibres 
in the portal areas of the liver; and staining of the fibres between the gastric 
glands, in the connective tissue and in the muscular mucosa of the stomach. 
Known ARA-positive and ARA-negative sera were used as controls.
5.2.1. The indirect immunofluorescence assay (IIF)
5.2.1.2. Detection of the antiendomysium antibodies
IgA-type AEM were measured by IIF, using the cryostat sections from the human 
umbilical cord as antigen substrate (195). Tissue sections were incubated with 
serum diluted at 1:10 and 1:100 with PBS, and FTTC-labelled rabbit antibody to 
human IgA (DAKO A/S, Glostrup, Denmark) was used as a secondary antibody. 
Under the fluorescence microscope (Jenalumar SH 50, ocular x 6.3, objective x 
25 and x 50) the presence of a honeycomb brilliant green network pattern along 
the peritubular muscle layer of the vessels on umbilical cord was taken as 
positive. Known AEM-positive and AEM-negative sera were used as controls.
5.2.2. The enzyme-linked immunosorbent assay (ELISA)
5.2.2.1. Detection of the antigliadin antibodies
AGA were determined by ELISA according to the method developed in the 
Department of Immunology, the University of Tartu. Briefly, wheat gliadin 
(Serva Diagnostica, Heidelberg, Germany) was dissolved in 70% ethanol 
(2 mg/ml), diluted at 1:100 in 0.05 M carbonate-bicarbonate buffer, and in­
cubated for 20 hours at +4°C. After washing with phosphate-buffered saline 
(PBS) (pH 7.4), the plates were saturated with 5% normal sheep serum (NSS) in 
PBS for 2 hours at +37°C. Further, the test sera and known AGA-positive and 
-negative control sera, diluted at 1:100 in 1% NSS-PBS, were analysed in dupli­
cate and incubated for 3 hours at +37°C. The plates were then washed again and
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alkaline phosphatase-conjugated antihuman IgG or IgA immunoglobulins 
(DAKO A/S, Glostrup, Denmark) in 1% NSS-PBS were added to each well at a 
dilution suggested by the manufacturer. After incubation for 20 hours at +20°C, 
the plates were washed and p-nitrophenyl-phosphate (Sigma, St Louis, USA) in 
diethanolamine magnesium chloride buffer, pH 9.8, was added. The reaction 
was stopped after 30 minutes with 3M sodium hydroxide. The optical density 
(OD) of the reaction product was measured at 405 nm. The results were calcu­
lated in enzyme immunosorbent units (EIU). The sera from 37 healthy indivi­
duals were used as references to establish a baseline absorbance value. Readings 
above three SD of the mean value were considered positive. The cut-off level 
for the tests was >120 EIU for IgA-type AGA and >8 EIU for IgG-type AGA. 
The inter-assay coefficient of variation of the AGA test results was 10.6% and 
the intra-assay coefficient of variation was 5.7%.
5.2.3. Statistical analysis
The prevalence of AGA in various groups of the patients was compared by 
means of the chi-square test with Yates’ correction. Analysis of variance 
(ANOVA) and the Student’s r-test were used to correlate the titres of AGA with 
different clinical markers; p<0.05 was considered significant.
5.3. Results
5.3.1. Antireticulin antibodies in the patients with ulcerative colitis
All the studied 50 UC patients and 53 individuals of the control group were 
negative for IgG-type ARA.
5.3.2. Antiendomysium antibodies in the patients with ulcerative colitis
All the 49 patients with UC studied and the 52 controls studied were negative 
for IgA-type AEM (sera for 1 UC and 1 healthy individual, both AGA-negative, 
were not available for this examination).
5.3.3. Antigliadin antibodies in the patients with ulcerative colitis
Altogether 17 out of the 50 (34%) patients with UC had positive IgA- or/and 
IgG-type AGA test result, in 5 of them both types of AGA were detected. Of the 
53 individuals in the control group, only 2 (4%) (both with IBS, males 24 and
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28 years of age) had positive IgG-type AGA (pcO.OOl for UC compared with 
controls). Figure 1 shows the distribution of IgA-and IgG-type AGA titres (EIU 
units) in the patients with UC and in the controls. There were significant 
differences in AGA titres between the UC patient group and controls. Median 
titres for IgA-type AGA were 76 EIU (range 0-219 EIU) in the patients with 
UC and 36 EIU (range 0-108) in the controls (p<0.001). For IgG-type AGA, the 
median titres were 5 EIU (range 0-50 EIU) in the UC patients and 2 EIU (range 
0-16) in the controls (p<0.01).
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Figure la,b. Titres of IgA-type (a) and IgG-type (b) antigliadin antibodies (AGA) in 
the patients with ulcerative colitis (UC) and in the controls. Discrimination between 
negative and positive test results is represented by the solid line.
The relationships between the extent of UC and the presence of different types 
of AGA are shown in Table 6. No significant difference between the extent of 
the disease and the presence of positive or negative AGA test results was 
observed. But five of the patients with both AGA, IgA- and IgG-types, had all 
extensive colitis. No correlation was found between the extent of disease and 
titre of AGA.
Table 6. The relation between the extent of ulcerative colitis (UC) and the presence of 
different types of antigliadin antibodies (AGA).
No of AGA positive UC patients
IgA AGA IgG AGA IgA + IgG 
AGA
Total
Disease extent 
Proctitis (n=19) 6 2 0 8
Left-sided (n=12) 1 1 0 2
Extensive (n=19) 0 2 5 7
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There was no significant correlation between the presence of AGA and disease 
activity, or duration of disease in the patients with UC (Table 7). In addition, 
these clinical markers were not related to the titre of AGA. No relationship was 
observed between the medication used and the presence of AGA (Table 7).
Table 7. The relationship between the presence of the antigliadin antibodies (AGA) and 
disease activity, disease duration and the medication used in the patients with ulcerative 
colitis (UC).
No of AGA positive UC patients
Disease activity
Remission (n=22) 8
Mild (n==10) 3
Moderate (n=14) 5
Severe (n=4) 1
Disease duration
< 5 years (n=21) 10
> 5 years (n=29) 7
Medication
Steroids (n=22) 6
Others or none (n=28) 11
5.4. Discussion
In 1965, Salem and Truelove (13) reported 12 patients with partial and 2 pa­
tients with subtotal villous atrophy among 60 patients with UC. The coexistence 
of coeliac disease with Crohn’s disease and UC has thereafter been described in 
several case-reports (131, 135, 136). In 1987, Breen et al. (131) reviewed 42 
rectal biopsies from a population of 438 patients with coeliac disease and, 
among them, found 3 patients with abnormal rectal biopsy having histopatho­
logic and clinical features of UC. An epidemiological survey of IBD in first- 
degree relatives of 162 coeliac patients showed the relative risk of IBD to be 
five times greater for first-degree relatives than that for the general population 
(133). In this study six of the 861 relatives had IBD, five of whom had UC and 
one CD. Taken together, these reports suggested that coeliac disease and IBD 
coexist more commonly than would be expected by chance. On the other hand, 
Collin et a l (196) examined 335 coeliac patients and found only one patient 
with concomitant IBD in comparison with 7 patients among 335 age and sex 
matched controls. Therefore an important question has been raised — is the 
coexistence of IBD and coeliac disease true or coincidental?
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The serum concentration of AGA has been used as a variable in screening 
for coeliac disease (197, 198). However, sensitivity and specificity levels are of 
around 80%, and the false-positive rate of AGA may be quite high (145, 153). 
The sensitivity and specificity of ARA and AEM are clearly greater than those 
of AGA in coeliac disease diagnosis (147, 150-153), but the testing of ARA 
and AEM is relatively expensive and time-consuming. Therefore, for coeliac 
disease screening a serial procedure using first AGA and then EMA analysis has 
been proposed. It is a procedure that may reduce the number of falsely positive 
tests and the number of small-bowel biopsy specimens (155).
In our study this problem was investigated by aiming to detect possible 
coeliac disease cases among the UC patients using all the three earlier described 
serological markers — AGA, ARA and AEM. AGA was found in 34% of the 
UC patients, but none of them had either IgG-type ARA or IgA-type AEM. 
Therefore, we can conclude that none of the UC patients we tested had coeliac 
disease, since ARA (140, 196) and AEM (141, 152, 153, 195, 199, 200) have 
been shown to be highly specific serological markers for coeliac disease.
However, there is another question left, why AGA, a type of antibodies 
frequently demonstrated in association with coeliac disease, are seen in 34% of 
the patients with UC in our study. Similar results were found also by Ferreira et 
al. (141) comparing the sensitivities and specificities of the AGA, ARA and 
AEM in the 117 patients with coeliac disease. The authors had in a disease 
control group a small number of patients with IBD (10 patients with UC and 21 
patients with Crohn’s disease). Positive AGA test was found in 10% of the 
patients with UC and in over 20% of the patients with Crohn’s disease, while 
ARA and AEM were negative in all patients. In another study, done by Volta et 
al. (201), IgG AGA were present in 19% of the 37 patients with UC and in 27% 
of the 26 patients with Crohn’s disease. Although these authors used IBD pa­
tients as disease controls for CD, their findings confirm our results.
In our study, we also found that the patients with extensive colitis only had 
both, IgA- and IgG-types of AGA. Based on the results gained we would 
suggest the following: as in the case of extensive colitis the gut mucosa is more 
extensively damaged, gut permeability may be increased. Therefore, we support 
the idea that the increased permeability to different food antigens of intestinal 
mucosa is also involved in the development of AGA in UC (202). But as none 
of the AGA positive UC patients did show any signs of malabsorption and ARA 
and AEM were negative, we considered endoscopy and small bowel biopsy not 
feasible for these patients.
In certain circumstances (e.g., in the presence of certain HLA haplotypes, 
such as HLA-DQ2) IBD may favour the onset of coeliac disease by altering 
intestine barrier function, thus allowing foreign antigens to breach the immune 
system (168, 203, 204). In approximately one-fourth of the patients reported, 
the diagnosis of IBD preceded that of coeliac disease (134). It is possible that 
some patients with latent coeliac disease have their disease diagnosed when an 
additional small bowel mucosal injury due to IBD overcomes their ability to
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compensate coeliac disease. In these cases, positive serological screening tests, 
mainly ARA and AEM, may help in selecting patients in whom coeliac disease 
is suspected for small-bowel biopsy. To solve the question of whether the 
development of AGA arises from similar mechanisms in both coeliac disease 
and IBD, further comparative studies of AGA (e.g., immunoblot, enzyme- 
linked immunospot assays [ELISPOT]) in coeliac disease and IBD are needed.
Although we could not find any patients with possible coeliac disease in our 
study, and regardless of the aetiology of the connection between the two dis­
orders, it is important that the clinicians would be aware of the association. 
Failure to recognise the possibility of coexistence of these two disorders can 
lead to clinical confusion and frustration, and can be detrimental to the patient. 
Any patient with an established diagnosis of coeliac disease who remains symp­
tomatic or develops new symptoms despite adhering to a gluten-free diet should 
be evaluated for the presence of IBD. Similarly, if patients with IBD have 
atypical symptoms or fail to respond to therapy, evaluation for the presence of 
underlying coeliac disease is essential (134).
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6. PART III: THE ASSOCIATIONS OF HLA CLASS II 
GENES AND OTHER CANDITADE GENES AND ANCA 
IN THE PATIENTS WITH INFLAMMATORY BOWEL 
DISEASE (PAPER IV)
6.1. Patients
A total of 53 unrelated patients with IBD were studied. Thirty-free serum samp­
les were obtained from the patients with UC (16 male and 17 female, median 
age 37.3 years) and 20 from the patients with CD (15 male and 5 female, mean 
age 36.0 years) attending the Department of Internal Medicine, the University 
of Tartu, or the University Outpatient Department. The diagnosis of UC and CD 
was based on the conventional criteria described earlier. Seventy healthy blood 
donors served as controls. The distribution of age, sex and ethnicity were 
comparable between the patients and the controls. All the immunogenetic stu­
dies were carried out by Dr. Hirv at the Institute of Immunology and Trans­
fusion Medicine (University of Liibeck School of Medicine, Liibeck, Germany). 
The study was approved by the Ethics Committee of the University of Tartu.
6.2. Methods
6.2.1. DNA extraction
Genomic DNA was extracted from 10 ml venous EDTA-blood or from 
peripheral blood leukocytes (controls) with QIAamp Blood Kit from QIAGEN 
according to the manufacturers’ instructions.
6.2.2. HLA-DRB and -DQB genotyping
The HLA-DRB 1 and HLA-DQB1 genotyping were performed by the INNO- 
LiPA DRB and DRQ key kit from Innogenetics. These HLA typing tests are 
based on the reverse hybridisation principle. Amplified biotinylated DNA 
material is chemically denatured, and the single strands are hybridised with 
specific oligonuclotic probes immobilised on membrane-based strips. With the 
exception of DQBl*0201-*0202, all other DQB1 alleles could be distinguished. 
Although the resolution at the allelic level is possible with the INNO-LiPA 
DRB key kit, only the discrimination at the HLA-DRB 1*01, *15, *16, *03, 
*04, *11, *12, *13, *14, *07, *08, *09, *10 allelic-group level was considered, 
except for the HLA-DRB 1*0103 allele, which could be distinguished from
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other HLA-DRB1*01 alleles. HLA-DRB1*15 alleles were specifically typed 
with the Micro SSP™ Allele Specific Class II DNA Typing Kit (One Lambda 
Inc.).
6.2.3. Detection of the antineutrophil cytoplasmic antibodies
Separation of peripheral blood neutrophils and detection of ANCA by DDF was 
performed according to the standard method described earlier.
6.2.4. TNF and the adhesion molecule polymorphism analysis
The detection of polymorphisms in the TNFa promoter at position -308 
(TNF1/2) and in the TNFp first intron (TNFB*l/2) with the help of PCR 
amplification and the subsequent digestion with the restriction enzyme Ncol 
were performed as described earlier (205, 206). The methods for identification 
of the adhesion molecule polymorphisms and primer sequences for the ampli­
fication of the investigated gene fragments are summarised in Table 8. Primer 
sequences for the amplification of the ICAM-1 Ig-like domain 3 and 5 were 
derived from the sequence described by Vora et al (207). PCRs were performed 
by using 30 ng template DNA in a final reaction volume of 50 |li1 in a 
GeneAmp9600 (Perkin Elmer) thermal cycler. The amplification conditions 
were optimised by changing the annealing temperature and time or extension 
time for each of the investigated adhesion molecule gene region. The poly­
morphism in exon 6 of the ICAM-1 gene (LysiAAG or Glu:GAG at codon 
469), coding for Ig-like domain 5 was identified through the incubation of the 
amplified 110 bp ICAM-1 exon 6 gene fragments with the restriction enzyme 
BstUl. The presence of the BstUl restriction site (CG*CG) resulted in 86 and 
24 bp fragments. The fragments were analysed by electrophoresis on 4% 
NuSieve gels and by following staining of the gels in 0.1% ethidium bromide.
For the identification of the polymorphisms in all other amplified adhesion 
molecule gene regions, the single-strand conformation polymorphism (SSCP) 
method was used. Primer sequences to analyse E- and L-selectin poly­
morphisms were kindly provided by Dr. K. Wenzel (Charite, Berlin) (208). The 
fragments were denatured and run on non-denaturing 12.5% or 20% polyacryl­
amide gels (Homogeneous PhastGels) from Pharmacia Biotech. The conditions 
for the horizontal electrophoresis and silver staining were optimised for each 
gene fragment and performed semi-automatically with the PhastSystem (Phar­
macia LKB Biotechnology AB). Figure 2 demonstrates the detection of the 
polymorphism in L-selectin EGF-like domain by PCR-SSCP analysis as an 
example of this method. To verify the SSCP results, the PCR products were 
sequenced.
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Table 8. Outline of adhesion molecule polymorphism’s analysis.
Polymorphism Method Primer sequence (S' to 30 PCR product
ICAM-1 (CD54)
Ig-like domain 3 PCR-SSCP Forward GATTGAAGAAGCCAGCAG 408 bp
(R/G241) Reverse GTCGTTGCCATAGGTGAC
Ig-like domain 5 PCR-RFLP Forward CCATCGGGGAATCAGTG 110 bp
(K/E469) Reverse ACAGAGCACATTCACGGTC
E-selectin (CD62E)
5'-untranslated region PCR-SSCP Forward TAACTAGCTACCCACGATTTCC 149 bp
(G/T98) Reverse ACTGACTTACCCAAAGTGAGAG
EGF-like domain PCR-SSCP Forward AGTAAT AGTCCTCCTCATC ATG 186 bp
(S/R128) Reverse ACCATCTCAAGTGAAGAAAGAG
Membrane domain PCR-SSCP Forward CAATTCTTCCTCATGACCTTTC 226 bp
(L/F554) Reverse CAAGACCATGACTTATCAATGAG
L-selectin (CD62L)
Lectin-like domain PCR-SSCP Forward TGTAAGTCTGCATAGGTCACAC 276 bp
(T/S49) Reverse TCAGTGAGAGATTTGTTGGTTC
EGF-like domain PCR-SSCP Forward C1T1GAGTACTAAAATGTAATCAC 198 bp
(F/L206) Reverse CCTAAGAAGAAGCAAAGAAAGG
PCR-RFLP — polymerase chain reaction-restriction fragment length polymorphism; PCR-SSCP — polymerase chain 
reaction-single-strand conformation polymorphism; EGF — epidermal growth factor
. .
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Figure 2. Representative single-strand conformation polymorphism (SSCP) analysis of 
the L-selectin epidermal growth factor (EGF)-like domain. An amplified 198-bp gene 
fragment was separated on PhastGel Homogeneous 20% gel. The amino acid poly­
morphism at codon 206 (F/L206) is caused by change from thymine to cytosine at 
nucleotide position 668, which results in a band shift in the electrophoretic analysis. 
Lanes 1, 2 and 3: heterozygous TC668. Lanes 4, 5, 6, and 8: homozygous TC668. Lane 
7: homozygous CC668.
6.2.5. Statistical analysis
The patients with UC, grouped together, and the patients with CD, grouped 
together, were compared with the controls. Associations with subsets of the UC 
and CD patients, divided by ANCA status, were also evaluated. The statistical 
significance was tested by the chi-square test. The Fisher’s exact test was used 
when appropriate (i.e., expected number <5). Significance was taken as p<0.05. 
By the correction of p values, the recommendations from Svejgaard and Ryder 
were taken into consideration (209). The correction factor for HLA-DRB 1 and 
HLA-DQB1 alleles was 12 (extremely infrequent alleles, ranging from 0 to 2, 
were not included in the number of comparisons). In the subgroups of UC or 
CD, stratified by ANCA, the correction factor was 24. In the phenotypic 
combination analysis the p values were corrected by a factor of 48. The cor­
rected p value is designated as pc. The odds ratio (OR) as a measure of associa­
tion was calculated using a Haldane’s modification as suggested by Svejgaard 
and Ryder (209).
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6.3. Results
6.3.1. Antineutrophil cytoplasmic antibodies in the patients with 
inflammatory bowel disease
In total, ANCA were detected by IIF in 27 of the 53 (50.9%) patients with IBD. 
Within UC and CD patients the presence of ANCA was different. Twenty-four 
of the 33 (72.7%) patients with UC and 3 of the 20 (15%) patients with CD 
were ANCA positive. The predominant ANCA staining pattern seen by IIF was 
perinuclear, only in one patient with UC cytoplasmic staining (cANCA) was 
revealed.
6.3.2. Adhesion molecule polymorphisms in the patients with 
inflammatory bowel disease
The observed allele frequencies of the investigated adhesion molecule poly­
morphisms in the control group and in the groups of patients suffering from UC 
and CD are shown in Table 9. There were no statistically significant differences 
in allele frequencies between the controls and the patients with UC or CD, or 
the patients considered as one group.
Table 9. Less common allele frequencies (%) of adhesion molecule genes in patients’ 
and controls’.
Polymorphism
Controls
(n=70)
UC patients 
(n=33)
CD patients 
(n=20)
ICAM-1
Ig-like domain 3 14.3 12.1 20.0
Ig-like domain 5 42.1 48.5 52.5
E-seleetin
5'-untranslated region 28.6 33.3 32.5
EGF-like domain 13.6 12.1 20.0
Membrane domain 3.6 7.6 2.5
L-selectin
Lectin-like domain 4.3 3.0 5.0
EGF-like domain 22.1 18.2 15.0
ICAM — intercellular adhesion molecule; EGF — epidermal growth factor; UC — 
ulcerative colitis; CD — Crohn’s disease
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Also, after dividing the patients into subgroups according to ANCA status, no 
significant differences were observed. Increased frequencies of the uncommon 
R241 ICAM-1 allele in the ANCA-negative UC and ANCA-positive CD 
subgroups of the patients, described by Yang et al. (91, 92), were not found in 
our study.
6.3.3. Tumour necrosis factor polymorphisms in the patients with 
inflammatory bowel disease
Allele frequencies and carriage rates of the TNF 1/2 polymorphism (in the TNFa 
promoter at position -308) and TNFB*l/2 polymorphism (in the TNFp first 
intron) were similar in the patients with UC and CD as well as control indi­
viduals (Table 10). Subgroup analysis showed borderline significant differences 
in the frequency of the uncommon TNF2 allele in the ANCA-positive and 
ANCA-negative subgroups of the patients with UC (20.8% vs. 0.0%, respec­
tively; p=0.051).
Table 10. Allele frequencies and carriage rates (%) of tumour necrosis factor (TNF) 
polymorphisms.
Allele frequencies
Polymorphism Allele 1 Allele 2 Allele 2 
carriage rate
TNF1/2
Controls (n=70) 83.6 16.4 30.0
UC patients (n=33) 84.8 15.2 24.2
ANCA-pos. UC (n=24) 79.2 20.8 33.3
ANCA-neg. UC (n=9) 100.0 0.0 0.0
CD patients (n=20) 80.0 20.0 40.0
TNFB*l/2
Controls (n=70) 32.9 67.1 92.9
UC patients (n=33) 28.8 71.2 78.8
ANCA -pos. UC (n=24) 33.3 66.7 79.2
ANCA-neg. UC (n=9) 16.6 83.4 77.8
CD patients (n=20) 37.5 62.5 95.0
ANCA — antineutrophil cytoplasmic antibodies; UC — ulcerative colitis; CD — 
Crohn’s disease
The TNFB * 1 allele was in linkage disequilibrium with the TNF2 allele 
(p<0.00001). Therefore the frequency of the TNFB*1 allele showed similar
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differences between the ANCA-positive and ANCA-negative UC patients, but 
did not reach statistical significance.
6.3.4. HLA class n  genes in the patients 
with inflammatory bowel disease
The distribution of HLA-DRB 1 alleles is shown in Table 11. The HLA- 
DRB 1*15 allele frequency was increased in the patients with UC compared 
with the controls (28.8% vs. 15.7%; OR=2.16; p=0.028). By contrast, the HLA- 
DRB 1*15 allele frequency was decreased in the patients with CD (2.5% vs. 
15.7%; C)R=2.20; p=0.027). There was only one carrier of this allele among the 
CD patients (5.0% vs.31.4% in the control group; OR=0.17; p=0.017). The 
apparently increased proportion of the CD patients carrying the HLA-DRB 1*01 
allele did not attain statistical significance compared with the controls (45.0% 
vs. 22.9%; p=0.051), possibly due to the small sample size. The HLA- 
DRB 1*0103 allele was infrequent in our population.
Table 11. Frequencies (%) of HLA-DRB 1 alleles in controls’ and patients’.
HLA-DRB1*
Controls
(n=70)
UC patients 
(n=33)
CD patients 
(n=20)
*01f 11.4 7.6 22.5
*0103 0.0 1.5 0.0
*03 15.7 9.1 17.5
*04 5.7 4.5 5.0
*07 11.4 12.1 5.0
*08 5.7 4.5 7.5
*09 0.0 1.5 5.0
*10 0.7 0.0 0.0
*11 14.3 9.1 20.0
*12 2.9 6.1 2.5
*13 11.4 10.6 7.5
*14 0.7 1.5 2.5
*15 15.7 28.8$ 2.5 §
*16 4.3 3.0 2.5
UC — ulcerative colitis; CD — Crohn’s disease 
t  Other than HLA-DRB 1*0103 
$ Compared with controls: P=0.028 
§ Compared with controls: P=0.027
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Dividing the patients by ANCA status, different distribution of the HLA-DRB1 
alleles in the subgroups of the UC patients was identified. Increased frequency 
of the HLA-DRB 1*15 alleles in the patients with UC could be reduced to the 
association of the HLA-DRB1*15 alleles with ANCA-positive UC (35.4% vs. 
15.7% in the controls; OR=2.93; p=0.004). The ANCA-negative UC patients 
had approximately the same HLA-DR*15 allele frequency as the controls 
(11.1% vs. 15.7%). Interestingly, the HLA-DRB1*03 and HLA-DRB1*11 
alleles have been found only in the UC patients with ANCA, but not among the 
ANCA-negative UC patients (Figure 3).
HLA-DRB 1*03 HLA-DRB1*H HLA-DRB 1*15
Figure 3. EtLA-DRBl*03, *11 and *15 allele frequencies (%) in the control group and 
in the antineutrophil cytoplasmic antibody ANCA-negative and ANCA-positive sub­
groups of the ulcerative colitis (UC) patients.
To support the hypothesis that the HLA-DRB 1*1502 allele may be responsible 
for the association of the HLA-DRB 1*15 alleles with UC, and particularly with 
their ANCA-positive subgroup, a specific typing of the HLA-DRB 1*15 alleles 
was performed. The HLA-DRB 1*1501 and -DRB 1*1502 alleles were both 
increased in the groups of the UC and ANCA-positive UC patients compared 
with the controls, but the HLA-DRB 1*1502 allele was infrequent in the 
population studied (Figure 4), and it was not the factor explaining the 
association of the HLA-DRB 1*15 alleles with UC and ANCA-positive UC.
As expected, the HLA-DR3-DQ2 haplotype was in strong linkage dise­
quilibrium with the uncommon TNF2 allele (p<0.00001). In the UC patients the 
HLA-DR3-DQ2 haplotype was not found without the TNF2 allele (15% of 
HLA-DR3-DQ2 carriers in the control group). The HLA-DQB1 alleles were 
found to be associated with UC or CD only in relation to strong linkage disequi­
librium with the HLA-DRB 1 alleles, always with lower p values.
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Figure 4. HLA-DRB 1*1501 and DRB 1*1502 allele frequencies (%) in the control 
group and in the antineutrophil cytoplasmic antibody ANCA-negative and ANCA- 
positive subgroups of the ulcerative colitis (UC) patients.
6.3.5. Associations between ANCA, HLA-DRB1*15 and TNF1/2 alleles in 
the patients with inflammatory bowel disease
Both the TNF2 and HLA-DRB 1*15 alleles showed an increased frequency in 
the ANCA-positive subgroup of the UC patients. 87.5% of the ANCA-positive 
UC patients were carriers of at least one of the HLA-DRB 1*15 or TNF2 alleles 
compared with 22.2% of the ANCA-negative UC patients (OR=18.97; p<0.001, 
pc=0.039) and 51.4% of the controls (OR=5.81; p=0.002) (Figure 5).
ggH L A -D R B 1*15/ TNF2 - /  +  g H L A -D R B  1* 15/T N F2 + / -  
8JH L A -D R B 1*I5/T N F2 + / +  g |§  HLA-DRB P I  5 /7N F 2
Figure 5. The proportion of HLA-DRB 1* 15/tumour necrosis factor (TNF) 2 phenotypic 
combinations in the control group and in the ulcerative colitis (UC) patients divided on 
the basis of the antineutrophil cytoplasmic antibody (ANCA) status.
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6.4. Discussion
For the first time the distribution of the HLA class II and TNF alleles in Esto­
nian patients with IBD was studied. The investigation of Estonian UC and CD 
patients is of particular interest because of the very low UC and CD incidence 
rates (1.5 and 0.3 per 100,000, respectively) (8-10) compared to other European 
populations (overall incidence about 1 to 10 per 100,000 for CD and from 5 to 
18 for UC) (6,7).
The results of this study provide further evidence of genetic heterogeneity 
within IBD, and also emphasise the importance of ethnic differences in disease 
susceptibility. Of particular note is the further evidence that HLA genes are 
involved in determing ANCA status. In the present study ANCA was positively 
associated with the HLA-DRB 1*15 and TNF2 alleles in the patients with UC. 
However, the role of ANCA as a subclinical genetic marker is not fully estab­
lished (88, 90, 93). Our data indicate that the HLA-DRB 1*15 and TNF2 alleles 
themselves, or more likely in a strong linkage with some other gene loci, might 
be the genetic markers for the susceptibility to develop ANCA-positive UC. 
The role of these markers could vary in different ethnic groups because of a 
different linkage with the primary susceptibility genes.
TNFa facilitates inflammatory cell infiltration by promoting adhesion of 
neutrophils and lymphocytes to endothelial cells, and up-regulates the expres­
sion of HL A molecules in human colonic cell lines and small intestinal epithe­
lial cells (210, 211). Although there is strong evidence to support the involve­
ment of TNFa in the pathogenesis of IBD, a primary role of the TNF 1/2 poly­
morphism in developing ANCA in UC patients or ANCA-positive UC is 
questionable. Recently Bouma et al. (212), studying the secretion of TNFa and 
TNF(3 in relation to polymorphisms at positions -308 and -238 in the TNFa 
gene in 30 patients with IBD and 12 healthy controls, demonstrated that the 
individuals homozygous for the TNF1 allele (in the TNFa promoter at position 
-308) produced significantly less TNFa than the individuals homozygous for 
the TNF2 allele. However, the number of the patients with the homozygous 
TNF2 allele was too low to allow stratification for the disease. Also, the 
frequency of the uncommon TNFa -308 allele 2 has been found to be decreased 
in patients with UC compared with healthy controls (176). These studies sug­
gest that a different genetic background may determine the height of the im­
mune response, and might, therefore, be responsible for different disease mani­
festations and severity in IBD.
The association of the HLA-DRB 1*15 alleles with ANCA-positive UC is 
not a generally accepted phenomenon. Studies in Japan and California (a mixed 
Jewish — non-Jewish population) have shown an association with the HLA- 
DRB1*1502 allele (167, 168, 213, 214). However, this has not been confirmed 
by Oxford (94) and Pittsburgh (93) studies, and almost certainly explained by 
the rarity of the DRB 1*1502 allele in North European non-Jewish Caucasoids
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(175). Recently, positive associations between the HLA-DRB 1*15 allele and 
UC were also reported in Dutch (169) and Spanish Caucasian (215) patients. To 
test the hypothesis that the HLA-DRB 1*1502 allele may be responsible for the 
association of the HLA-DRB 1*15 alleles with UC, a specific typing of the 
HLA-DRB 1*15 alleles was carried out. The present study reveal that the HLA- 
DRB 1*1502 allele is infrequent in our population and the association of the 
HLA-DRB 1*15 alleles with ANCA-positive UC could not be attributed to the 
HLA-DRB 1*1502 allele. These observations underline the importance of ethni­
city in studying the genetics of IBD.
Remarkable dissimilarities were found in the distribution of HLA-DR- 
DQ/TNF1/2 phenotypic combinations in the controls compared with the pa­
tients suffering from UC. There is a disagreement regarding the role of the well- 
known HLA-DR3-DQ2/TNF2 haplotype on the outcome of IBD. A protective 
effect of the HLA-DR3-DQ2 haplotype against IBD has been reported recently 
(215, 216). At the same time, the HLA-DRB 1 *0301-DQB1 *0201/TNF2 (HLA- 
DR3-DQ2/TNF2-positive patients) haplotype has been demonstrated to be pre­
dictive of extensive disease in patients with UC (88, 94). In addition, a signifi­
cant association between the carriage of the TNF2 allele and ANCA positivity 
in UC has been shown by two recent studies (88, 172) and in the present study. 
We suspect a different influence of the TNF2 allele and HLA-DR3-DQ2 haplo­
type on the outcome of IBD, as has been recently shown for fistulising CD 
(217).
The HLA-DRB 1*0103 allele has been demonstrated to be predictive of 
extensive disease or severe disease requiring surgery, and may be associated 
with the presence of extra-intestinal manifestations (88, 94, 172). This allele 
was infrequent in our population and, therefore, no conclusions about the role of 
this allele in the pathogenesis of IBD could be made.
This is the first study investigating the possible involvement of E-selectin 
and L-selectin in addition to other adhesion molecule polymorphisms (ICAM- 
1), in the pathogenesis of IBD. The intercellular adhesion molecule 1 (ICAM-1) 
is one of the most important cell surface adhesion molecules and is expressed 
on the luminal surface of activated venular endothelial cells and macrophages 
during antigen presentation to T cells. We could not confirm the previous ob­
servation about the increased frequency of the uncommon ICAM-1 R241 allele 
among ANCA-negative UC and ANCA-positive CD patients (92). This discre­
pancy might be attributed to ethnic differences. In addition to the differences in 
the UC and CD incidence rates in Estonians, there was a markedly higher fre­
quency of the less common R241 allele in our control group (14.3%) compared 
'with the control group used by Yang et al. (6.4%) (92). The investigated poly­
morphisms in the gene regions encoding for E-selectin and L-selectin, seemed 
to have no influence on the aetiopathogenesis or outcome of IBD.
Statistical associations between HLA-DRB 1 and TNFa polymorphisms and 
subgroups of IBD patients were observed. These polymorphisms might be 
directly associated with IBD or could be linked to certain susceptibility genes.
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At least in some ethnic groups, ANCA appears to be a useful marker in com­
bination with genetic markers such as the HLA-DRB 1*15 alleles, by dividing 
IBD patients into more homogeneous subgroups with putative disparate patho­
genic pathways. The HLA-DR3-DQ2 haplotype and the TNF2 allele, in strong 
linkage disequilibrium with each other, might have different influences on the 
outcome of IBD. Further studies with a larger number of patients and stratified 
for the disease are needed to test this hypothesis.
In conclusion, both UC and CD show considerable clinical and genetic hetero­
geneity, but available evidence suggests that chronic intestinal inflammation 
develops as a result of a complex interplay between shared susceptibility genes 
and environmental factors. The type of inflammation that develops probably 
depends on the possession of “disease-specific” genes; further genetic influence 
may determine the clinical behaviour of the disease. In addition to HLA and 
cytokine gene studies, genome-wide scanning in IBD has become the focus of 
intensive scientific interest. The regions on chromosomes 3, 7, 12 and 16 are 
known to contain a number of potential positional candidate genes (166). There is 
now a real hope that these studies will lead to an understanding of the basic 
pathophysiology of these complex disorders with clinical and therapeutic 
benefits.
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7. CONCLUSIONS
1. ANCA were detected in 49-58% of the patients with UC, in 19-24% of the 
patients with CD and in 2-4% of the healthy controls. There are no signifi­
cant differences in the prevalence of ANCA compared with the data ob­
served in different European countries. In both UC and CD, there was no 
correlation between the presence of ANCA and the duration or extent of 
IBD. The presence of ANCA in a rather great amount of the patients with 
CD limits their diagnostic value in distinguishing between UC and CD.
2. The predominant ANCA staining pattern seen by IIF in IBD was perinuclear. 
In ELISA assays only 18% of the serum samples reacted positively to pro- 
teinase-3, myeloperoxidase, lactoferrin, and cathepsin G. Accordingly, other 
unknown antigens can be the targets for ANCA in the patients with IBD.
3. Of the non-organ-specific antibodies studied by IIF in titre 1:10 and 1:100, 
ANA, SMA, TMA and PCA were detected in the patients with IBD or 
healthy controls. In titre 1:100 8% of the UC patients, 3% of the CD patients 
and 2% of the controls had them. Statistically significantly higher prevalence 
of these autoantibodies in the UC patients, suggesting autoimmune mecha­
nisms, could not have been revealed in our study, probably due to small 
study groups. All the ANA positive sera were screened by ELISA for Sm, 
RNP, SS-A, SS-B, Scl-70 and Jo-1 antibodies. The sera of the patient with 
extensive UC and AIH reacted positively to the Scl-70 antigen.
4. AGA was found in 34% of the UC patients and 4% of the controls. There 
was no correlation between the presence of AGA and the duration or extent 
of the disease, or disease activity and the medication used. The patients with 
extensive UC only had both of AGA, IgA- and IgG-types. Probably in­
creased permeability in the case of extensive UC may favour dietary gliadin 
to break into the immune system and creation of these antibodies. None of 
the patients studied had coeliac disease, since ARA and AEM were negative.
5. The HLA-DRB 1*15 allele frequency was increased in the Estonian patients 
with UC in comparison with the healthy controls. ANCA may be a useful 
marker by dividing IBD patients, as the TNF2 and HLA-DRB 1*15 alleles 
were associated with the ANCA-positive UC subgroup. The HLA-DR3-DQ2 
haplotype was in strong linkage disequilibrium with the uncommon TNF2 
allele in the patients with IBD. We could not confirm the previous obser­
vation of increased frequency of the uncommon ICAM-1 R241 allele among 
the ANCA-negative UC and ANCA-positive CD patients. Studying poly­
morphisms in the gene regions encoding for E-selectin and L-selectin, no 
statistical differences in allele frequencies between the patients with IBD and 
healthy controls were found.
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KOKKUVOTE
POLETIKULINE SOOLEHAIGUS 
Immuungeneetiline uuring
Haavandiline koliit ja Crohni tobi on kroonilise kulu, selgusetu etioloogia ning 
korduvate agenemistega kulgevad jame- ja peensoolehaigused, kus peale soole 
tekivad haiguslikud muutused ka teistes elundites. Erialakiijanduses kasitletakse 
neid koos poletikulise soolehaigusena. Mdlema haiguse pohjused, tekkemehha- 
nism, seos soolevaliste haigusnahtude ja mitmete kaasuvate autoimmuunsete 
haigustega on seniajani teadmata. Poletikulise soolehaiguse patogeneesis on 
oluline mitmete faktorite, nii geneetilise eelsoodumuse, eksogeense vailandava 
(itrigger) faktori kui ka modifitseerivate faktorite koostoime, mille tulemusena 
kaivitub pdletikuprotsess ning immuunsusteemi vahendusel tekib koekahjustus.
Poletikuline soolehaigus esineb arenenud riikides suhteliselt sageli. Esmas- 
haigestumus on piirkonniti erinev, olles haavandilise koliidi puhul keskmiselt 
5-18 juhtu ning Crohni tove puhul 1-10 juhtu 100 000 inimese kohta aastas. 
Eestis 1973-1993 tehtud tagasivaatavast epidemioloogilisest uurimusest selgus, 
et haigestumus haavandilisse koliiti (1,5 haiget 100 000 elaniku kohta aastas) ja 
selle levimus (31,0 haiget 100 000 elaniku kohta) Eestis erines teiste maade 
omast tile kumne korra. Crohni tove esinemine Eestis oli aga erakordselt tagasi- 
hoidlik (haigestumus 0,3; levimus 4,2), olles ligi 30 korda vaiksem kui naiteks 
Skandinaaviamaades. Niivord madala haigestumuse pohjused ei ole teada ning 
ainult taiendavad epidemioloogilised, immunoloogilised, geneetilised ja mikro- 
bioloogilised uuringud vdimaldavad valja tuua poletikulise soolehaigusega 
seotud isearasusi eestlastel.
Kaesoleva too eesmargid:
1) uurida neutrofiilide tsutoplasma vastaste antikehade (ANCA) esinemissage- 
dust ja kliinilist vaartust haavandilise koliidi ning Crohni tdve haigetel (I, II);
2) maarata ANCA immunofluorestsentsmuster ning iseloomustada ELISA- 
meetodil ANCA antigeenset struktuuri, kasutades antigeense substraadina 
miieloperoksudaasi, proteinaas-3, laktoferiini ja katepsiin G (I);
3) maarata mitmete mittespetsiifiliste autoantikehade esinemissagedus ja kliini- 
line vaartus haavandilise koliidi ja  Crohni tdve haigetel ning uurida ANA- 
positiivseid seerumeid ELISA-meetodil ekstraheeritavate tuumaantigeenide 
vastaste [Sm (Smith), RNP, SS-A (Ro), SS-B (La), Scl-70, Jo-1] antikehade 
suhtes (II);
4) uurida retikuliini (ARA), endommisiumi (AEM) ja gliadiini (AGA) antike­
hade esinemissagedust haavandilise koliidiga patsientide hulgas ja leida kor- 
relatsioonid nimetatud antikehade ja erinevate kliiniliste naitajate vahel (III);
5) uurida polumorfisme HLA-DR ja -DQ, tuumori nekroosi faktori (TNF), E- 
selektiini, L-selektiini ja intratsellulaarse adhesiooni molekuli 1 (ICAM-1)
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geenidtes poletikulise soolehaigusega patsientidel ning leida nende markerite 
ja ANCA vahelised seosed (IV).
I. Erinevate autoantikehade esinemissagedus ja tahendus poletikulise 
soolehaiguse korral (artiklid I ja II)
Uuriti vastavalt 59 ja 77 haavandilise koliidi ning 17 ja 31 Crohni tove patsienti 
(artiklid I, II). Kontrollgruppidesse kuulus vastavalt 111 ja l08 soole arritus- 
siindroomiga patsienti voi tervet isikut.
IgG ANCA maarati kaudsel immunofluorestsentsmeetodil (IIF), kasutades 
antigeenina etanoolis fikseeritud neutrofiile. IgG-tiiiipi tuumavastased (ANA), 
mitokondritevastased (AMA), silelihaskoevastased (SMA), retikuliinivastased 
(ARA), maksa-neeru mikrosoomide vastased (LKMA), parietaalrakkudevasta- 
sed (PCA) ja kilpnaarme mikrosoomide vastased (TMA) antikehad maarati 
samuti IIF-meetodil, kasutades antigeense substraadina erinevate kudede 
kriiostaatloike. Immunoensiiiimmeetodit (ELISA) kasutati miieloperoksiidaasi-, 
proteinaas-3, laktoferiini- ja katepsiin G vastaste antikehade ning ekstraheerita- 
vate tuumaantigeenide vastaste [Sm, RNP, SS-A (Ro), SS-B (La), Scl-70, Jo-1] 
antikehade maaramiseks.
IgG-tuiipi ANCA leiti 49-58%-l haavandilise koliidi ning 19-24%-l Crohni 
tove haigetest (artikkel I, II). Kontrollriihmas oli ANCA statistiliselt oluliselt 
harvem, 2-4%-l. Pohiliselt esines pANCA. Nii haavandilise koliidi kui ka 
Crohni tove korral puudus seos haiguse ulatuse ja kestuse ning ANCA esine- 
mise vahel. Samas oli Crohni tdve haigetel ANCA vaid jamesoole haaratusega 
patsientide hulgas, mis viitab jamesoole osatahtsusele ANCA tekkes. Kirjan- 
duses esinenud viidetele, et ANCA voib aidata eristada haavandilist koliiti 
Crohni tovest, sest neid antikehi on vahestel Crohni tove haigetel, me oma toos 
kinnitust ei leidnud. ANCA oli 19-24%-l Crohni tove haigetest, seega voib 
jareldada, et ANCA kasutamine haavandilise koliidi ja Crohni tove eristamisel 
on piiratud. Ainult 18%-1 haavandilise koliidi ja Crohni t5ve haigetest olid 
miieloperoksiidaasi-, proteinaas-3, laktoferiini- voi katepsiin G vastased anti­
kehad.
IgG-tuiipi ANA, SMA, TMA ja/voi PCA leiti 25%-l haavandilise koliidi 
haigetel, 26%-l Crohni tove haigetest olid ANA voi SMA. Kontrollriihmas olid 
ANA, SMA, TMA ja/voi PCA 12%-1. Enamikul haavandilise koliidi ja Crohni 
tove haigetel esinesid need antikehad seerumi lahjenduses 1:10. Ainult kuuel 
(8%) haavandilise koliidi ja iihel (3%) Crohni tove haigel ning kahel (2%) 
kontrollriihma kuuluval isikul oli neid antikehi lahjenduses 1:100.
Uheteistkiimnest ANA-positiivsest seerumist, mida uuriti edasi ELISA- 
meetodil Sm, RNP, SS-A, SS-B, Scl-70 ja Jo-1 antikehade suhtes, reageeris iiks 
positiivselt Scl-70 antigeenile. Scl-70 vastaseid antikehi leitakse sageli siis- 
teemse sklerodermiaga haigetel. Antud juhul oli tegemist 23-aastase pankoliiti
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podeva naispatsiendiga, kellel kaasuva haigusena oli ka autoimmuunne hepatiit. 
Siisteemsele sklerodermiale viitavaid siimptomeid tal ei leitud.
II. Retikuliini, endomutisiumi ja gliadiini antikehade esinemissagedus ja 
tahendus haavandilise koliidi haigeil (artikkel III)
Retikuliini antikehade (ARA), endomiiiisiumi antikehade (AEM) ja gliadiini 
antikehade (AGA) esinemist uuriti 50-1 haavandilise koliidi haigel ning 53-1 
kontrollgrapi isikul.
ARA ja AEM maarati IIF-meetodil, AGA maarati ELISA-meetodil.
IgA- ja/voi IgG-tiiiipi AGA esines 34%-l haavandilise koliidi haigetest. 
Puudus korrelatsioon AGA esinemise ning haavandilise koliidi kestuse, ulatuse, 
haiguse aktiivsuse ja kasutatud ravimite vahel. Siiski, koigil viiel patsiendil, 
kellel leiti nii IgA- kui ka IgG-tiiiipi antikehad, esines pankoliit. Seetdttu vdib 
vaita, et mida ulatuslikum on soolekahjustus, seda toenaolisem on antigeeni 
tungimine organismi ning ka vastavate antikehade produtseerimine immuun- 
siisteemi poolt. Ainult 2%-l kontrollgrupi haigetest esinesid gliadiini antikehad. 
Et ARA ja AEM olid koikidel juhtudel negatiivsed, siis voib vaita, et nimetatud 
uuringugruppides tsoliaakiat ei olnud.
III. Polumorfismid HLA-DR ja -DQ, tuumori nekroosi faktori (TNF) ning 
adhesiooni molekuli geenides poletikulise soolehaigusega patsientidel; 
nende markerite ja ANCA seosed (artikkel IV)
Uuriti poliimorfisme HLA-DR ja -DQ, tuumori nekroosi faktori (TNF), E-selek- 
tiini, L-selektiini ja intratsellulaarse adhesiooni molekuli 1 (ICAM-1) geenides 
53-1 pdletikulise soolehaigusega patsiendil ja 70-1 tervel isikul ning maarati 
nende markerite ja ANCA vahelised seosed.
HLA genotiipiseerimiseks kasutati poordhiibridisatsiooni meetodit ning 
jaijestusspetsiifilisi praimereid. TNF-i ja adhesioonimolekulide poliimorfismide 
uurimiseks kasutati poliimeraasi ahelreaktsiooni (PCR) ning seejarel restrikt- 
sioonifragmentide pikkuse poliimorfismi meetodit (RFLP) voi iiheahelalise 
DNA konformatsioonilise poliimorfismi (SSCP) analiiiisi.
HLA-DRB 1*15 alleeli oli haavandilise koliidi haigetel statistiliselt oluliselt 
sagedamini, vdrreldes kontrollgrupiga (28,8% vs. 15,7%; p=0.028). ANCA- 
positiivsetel haavandilise koliidi haigetel oli statistiliselt oluliselt sagedamini 
TNF2 ja HLA-DRB 1*15 alleeli. 87,5% ANCA-positiivsetest haavandilise 
koliidi haigetest olid vahemalt iihe nimetatud alleeli kandjad, vorreldes 22,2% 
ANCA-negatiivsete haavandilise koliidi haigetega (p<0,001). HLA-DRB 1*15 
alleeli spetsiifiline tiipiseerimine naitas, et HLA-DRB 1*1501 alleel seondub 
ANCA-positiivse haavandilise koliidi grupiga.
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HLA-DR3-DQ2 haplotutip oli tugevasti seotud harva esineva TNF2 
alleeliga. Haavandilise koliidi haigetel oli HLA-DR3-DQ2 haplotiiiip alati 
kombinatsioonis TNF2 alleeliga. Uuritud E-selektiini, L-selektiini ning ICAM-1 
poliimorfismide ja ANCA-positiivsete ning -negatiivsete haavandilise koliidi 
gruppide vahel statistiliselt olulisi erinevusi ei leitud.
IV. Kokkuvote
1. ANCA leiti 49-58%-l haavandilise koliidi, 19-24%-l Crohni tove haigetest 
ning 2-4%-l kontrollriihmas. Kuigi haigestumus haavandilisse koliiti ja 
Crohni toppe on Eestis madal, ei ole ANCA esinemises erinevusi teiste 
Euroopa maadega vorreldes. Nii haavandilise koliidi kui ka Crohni tove 
korral puudus seos haiguse ulatuse ja kestuse ning ANCA esinemise vahel. 
ANCA kasutamine haavandilise koliidi ja Crohni tove eristamisel on piira- 
tud, sest neid antikehi oli arvestataval hulgal ka Crohni tove haigetel.
2. Pohiliselt esines perinukleaarset tuiipi ANCA (pANCA). Muud antigeenid, 
mitte miieloperoksiidaas, proteinaas-3, laktoferiin ja katepsiin G, on ilmselt 
primaarseks ANCA-le, kuna ainult 18% haavandilise koliidi ja Crohni tove 
haigetest reageeris ELISA-uuringutel eespool nimetatud antigeenidele posi- 
tiivselt.
3. Muudest uuritud antikehadest olid haavandilise koliidi ja Crohni tove haige­
tel ANA, SMA, TMA ja PCA. Uldiselt ilmnesid nimetatud antikehad mada- 
las seerumi lahjenduses, vaid 8%-l haavandilise koliidi, 3%-l Crohni tove 
haigetest ning 2%-l kontrollriihmas leiti neid seerumi lahjenduses 1:100. 
Statistiliselt toeparast antikehade sagedasemat esinemist haavandilise koliidi 
haigetel, mis viitaks autoimmuunmehhanismide osatahtsusele, ei leitud ning 
toenaoliselt oli see tingitud uuringugruppide vaiksusest. Uheteistkiimnest 
ANA-positiivsest seerumist, mida uuriti ELISA-meetodil Sm, RNP, SS-A, 
SS-B, Scl-70 ja Jo-1 antikehade suhtes, reageeris iiks positiivselt Scl-70 anti- 
geenile. Tegemist oli 23-aastase pankoliiti podeva naispatsiendiga, kellel 
kaasuva haigusena oli ka autoimmuunne hepatiit.
4. AGA leiti 34%-l haavandilise koliidi haigetest ning 4%-l kontrollriihma isi- 
kutest. I^iudus korrelatsioon AGA esinemise ning haavandilise koliidi kes­
tuse, ulatuse, haiguse aktiivsuse ja kasutatud ravimite vahel. Molemat tiiiipi 
AGA koosesinemist, IgA- ja IgG-tuiipi, leiti ainult pankoliidiga patsientide 
hulgas. Seetottu voib vaita, et mida ulatuslikum on soolekahjustus, seda toe- 
naolisem on antigeeni tungimine organismi ning ka vastavate antikehade 
produtseerimine immuunsusteemi poolt. Et ARA ja AEM olid koikidel juh- 
tudel negatiivsed, siis voib vaita, et nimetatud uuringugruppides tsoliaakiat 
ei olnud.
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5. Haavandilise koliidi haigetel oli HLA-DRB 1*15 alleeli statistiliselt oluliselt 
sagedamini kontrollriihma isikutega vorreldes. ANCA-positiivsetel haavan­
dilise koliidi haigetel oli statistiliselt oluliselt sagedamini TNF2 ja HLA- 
DRB 1*15 alleeli. Seetottu voib ANCA kombinatsioonis geneetiliste marke- 
ritega osutuda oluliseks markeriks, mis voimaldab jagada poletikulise soole- 
haigusega patsiendid homogeensematesse alagrappidesse. Poletikulise soole- 
haigusega patsientide hulgas oli HLA-DR3-DQ2 haplotiiiip tugevasti seotud 
harva esineva TNF2 alleeliga. Uuritud E-selektiini, L-selektiini ning ICAM- 
1 polumorfismide ja ANCA-positiivsete ning -negatiivsete haavandilise 
koliidi gruppide vahel statistiliselt olulisi erinevusi ei leitud.
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Table 2. Relationship between presence o f antigliadin anti­
bodies (A G A ) and disease activity, disease duration, and 
medication used in patients with ulcerative colitis (UC)
No of AGA-positive UC patients
Disease activity
Remission (« =  22) 8
Mild (n =  10) 3
M oderate {n =  14) 5
Severe (n =  4) 1
D isease duration
< 5  years (n =  21) 10
> 5  years (n =  29) 7
Medication
Steroids (n =  22) 6
O ther or none (n  = 28) 11
Antiendomysium antibodies
All 49 patients with U C  studied and the 52 controls 
studied were negative for IgA-type AEM  (sera for 1 UC  
patient and 1 healthy individual, both AGA-negative, 
were not available for this examination).
Discussion
In 1965, Salem and Truelove4 reported 12 patients with 
partial and 2 patients with subtotal villous atrophy 
among 60 patients with UC. The coexistence of CD with 
Crohn’s disease and UC has since been described in 
several case reports.61113 In 1987, Breen et al.7 reviewed 
42 rectal biopsies from a population o f 438 patients with 
CD and found 3 patients with abnormal rectal biopsy 
results who had histopathologic and clinical features of 
UC. An epidemiological survey of IBD in the first- 
degree relatives o f 162 celiac patients showed the 
relative risk of IBD to be five times greater for first- 
degree relatives than for the general population.10 
Taken together, these reports suggested that CD and 
IBD  coexist more commonly than would be expected by 
chance. On the other hand, Collin et al.23 examined 335 
celiac patients and found only 1 patient with concomi­
tant IBD, in comparison with 7 patients among 335 age, 
and sex-matched controls. Therefore an important 
question has been raised— is the coexistence of IBD and 
CD true or coincidental?
In our study, we investigated this problem by aiming 
to detect possible CD cases among UC patients, using 
serological markers— A G A , A R A , and AEM. A G A  
was found in 34% of UC patients, but none of these had 
either IgG-type A R A  or IgA-type AEM. Therefore, we 
can conclude that none of the UC patients we tested had 
CD, since ARA'7 and AEM 18,22-24"26 have been shown to 
be highly specific serological markers for CD.
K. Kull et al.: Antigliadin antibodies in UC
However, another question remains; why A G A , the 
type of antibodies frequently demonstrated in associa­
tion with CD, were seen in 34% of the patients with UC  
in our study. Results similar to ours were reported by 
Ferreira et al.,18 who compared the sensitivities and 
specificities of A G A , AR A , and AEM  in 117 patients 
with CD. In their disease control group, these authors 
had a small number of patients with IBD (10 patients 
with UC and 21 patients with CD). A  positive A G A  test 
result was found in 10% of the patients with UC and 
in over 20% of the patients with CD, while A R A  and 
AEM  were negative in all patients. In another study, by 
Volta et al.27, IgG A G A  were present in 19% of 37 
patients with UC and in 27% of 26 patients with CD. 
Although these authors used IBD patients as disease 
controls for CD, their findings confirm our results.
In our study, we also found that patients with exten­
sive colitis more frequently had IgA +  IgG-types of 
A G A  than patients with proctitis. But as none of the 
AGA-positive UC patients showed any signs of mal­
absorption, and as A R A  and AEM  were negative, we 
considered that endoscopy and small bowel biopsy were 
not indicated for these patients. Based on these results, 
we suggest that, as the gut mucosa is more extensively 
damaged in extensive colitis, gut permeability may be 
increased. Therefore, we support the idea that the in­
creased permeability o f the intestinal mucosa to differ­
ent food antigens also involves the presence A G A  in 
UC.28
In certain circumstances (e.g., in the presence of 
certain human leukocyte antigen haplotypes, such as 
H LA-DQ2), UC may favor the onset o f CD by altering 
intestine barrier function, thus allowing foreign antigen 
to breach the immune system.2” ' In approximately one- 
fourth of the patients exported, the diagnosis of IBD  
preceded that of CD.11 In these patients, positive sero­
logical screening tests, mainly A R A  and AEM , may 
help in selecting patients in whom CD is suspected for 
small-bowel biopsy. To resolve the question of whether 
the presence of A G A  a rises from similar mechanisms 
in both CD and UC, further comparative studies of 
A G A  (e.g., with immunoblot, enzyme-linked immuno- 
spot assays (ELISPOT), in CD and U C  are needed.
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AEM-positive and AEM-negative sera were used as 
controls.
AGA. No relationship was observed between the medi­
cation used and the presence o f A G A  (Table 2).
Statistics
The prevalence o f A G A  in various groups o f patients 
was compared by means of the %2 test with Yates’ cor­
rection. Analysis o f variance (AN O V A ) and Student’s 
/-test were used to correlate the titers fo A G A  with 
different clinical markers; P  <  0.05 was considered 
significant.
Results
Antigliadin antibodies
In total, 17 of the 50 patients with UC (34%) had a 
positive IgA- or/and IgG-type A G A  test result; in 5, 
both types of A G A were detected. Of the 53 individuals 
in the control group, only 2 (4%) (both with IBS; men, 
aged 24 and 28 years) were positive for IgG-type A G A  
(P <  0.001 for UC compared with controls). Figure 1 
shows the distribution o f IgA-and IgG-type A G A  titers 
(EIU units) in patients with UC and in controls. There 
were significant differences in A G A  titers between the 
UC patient group and controls. Median titers for IgA- 
type A G A  were 76 EIU (range, 0-219 EIU) in patients 
with UC and 36 EIU (range, 0-108 EIU) in controls 
(P <  0.001). For IgG-type AG A, the median titers were 
5 EIU (range, 0-50 EIU) in UC patients and 2 EIU  
(range, 0-16) in controls (P < 0.01).
The relations hips between the extent of UC and the 
presence of different types of A G A  are shown in Table
1. N o significant difference between the extent of the 
disease and positive or negative A G A test results was 
observed. But five of the patients with both A G A , IgA- 
and IgG-types, had extensive colitis. No correlation 
was found between the extent of disease and the titer of 
AGA.
There was no significant correlation between the 
presence of A G A  and disease activity or duration of 
disease in the patients with U C  (Table 2). In addition, 
these clinical markers were not related to the titer of
Antireticulin antibodies
All 50 UC patients and 53 controls were negative for 
IgG-type ARA.
Fig. la,b. Titers of a IgA-type and b IgG-type antigliadin 
antibodies (AGA) in patients with ulcerative colitis (UC) and 
controls. Discrimination between negative and positive test 
results is represented by the solid line
Table 1. Relation between extent of ulcerative colitis (UC) and presence of different 
types of antigliadin antibodies (A G A )__________________________________________
No of AGA-positive UC patients
IgA AGA IgG A G A IgA + IgG A GA Total
Disease extent
Proctitis (n = 19) 6 2 0 8
Left-sided (n = 12) 1 1 0 2
Extensive (n = 19) 0 2 5 7
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patients with UC (25 men and 25 women, aged 14-75 
years; mean, 43 years) attending the Department of 
Internal Medicine, University o f Tartu, or the Univer­
sity Outpatient Department. The diagnosis o f UC  
was based on conventional criteria recommended by 
Lennard-Jones.19 U C  patients were classified according 
to disease extent, disease activity, and disease duration 
at the time the blood sample was obtained. The extent of 
colitis was evaluated in 43 patients by colonoscopy, and 
in 7 by radiological investigation. Nineteen patients had 
proctitis, 12 left-sided colitis, and 19 extensive colitis. 
Disease activity was assessed by the criteria o f Truelove 
and Witts.20 U C  was characterized as mild, moderate, or 
severe, based on equal weighting of the following six 
factors: diarrhea, fever, tachycardia, anemia, erythro­
cyte sedimentation rate, and physical examination. 
Twenty-two of the 50 UC patients were in clinical remis­
sion, 10 had mild disease, 14 moderate disease, and 4, 
severe disease. Twenty-two of the 50 patients with UC  
were treated with a combination o f systemic or topical 
steroids and sulfasalazine or mesalazine. The other 
patients received no medication, or sulfasalazine or 
mesalazine only. Finally, duration o f disease was consid­
ered: 21 patients had been suffering from UC less than 
5 years and 29 patients for 5 years or more.
The control group consisted o f 53 individuals age- 
and sex-matched with the UC group (24 men and 29 
women; aged 16-79 years, mean, 43 years). Sixteen 
patients had irritable bowel syndrome (IBS) (9 men and 
7 women; aged 16-62 years, mean, 40 years) and 37 
were healthy individuals (15 men and 22 women; aged 
17-79 years; mean, 46 years) with no history of gas­
trointestinal or other chronic diseases.
Methods
Ten ml o f venous blood was taken from each subject 
and stored at -2 0 °C  until analyzed for IgA- and IgG- 
type A G A , IgG-type A R A , and IgA-type AEM.
Antigliadin antibodies
AGA were determined by enzyme-linked immuno­
sorbent assay (ELISA) according to the method 
developed at the Department o f Immunology, 
University o f Tartu. Briefly, wheat gliadin (Serva 
Diagnostica, Heidelberg, Germany) was dissolved in 
70% ethanol (2 mg/ml), diluted 1:100 in 0.05 M carbon­
ate-bicarbonate buffer, and incubated for 20 h at +4°C. 
After being washed with phosphate-buffered saline 
(PBS) (pH 7.4), the plates were saturated with 5% 
normal sheep serum (NSS) in PBS for 2h at +37°C. 
Further, the test sera and known AGA-positive and 
-negative control sera, diluted 1:100 in 1% NSS-PBS,
were analyzed in duplicate and incubated for 3h at 
+37°C. The plates were then washed again and alkaline 
phosphatase-conjugated antihuman IgG or IgA immu­
noglobulins (Dako, Glostrup, Denmark) in 1% NSS- 
PBS were added to each well at the dilution suggested 
by the manufacturer. After incubation for 20 h at 
+20°C, the plates were washed and p-nitrophenyl-phos- 
phate (Sigma, St. Louis, MO, USA ) in diethanolamine 
magnesium chloride buffer, pH 9.8, was added. The 
reaction was stopped after 30min with 3M sodium hy­
droxide. The optical density (O D ) of the reaction prod­
uct was measured at 405 nm. The results were calculated 
in enzyme immunosorbent units (EIU). The sera from 
the 37 healthy individuals were used as references to 
establish a baseline absorbance value. Readings above 
three SD of the mean were considered positive. The cut­
off level for tests was a  120 EIU for IgA-type A G A  and 
a 8  EIU for IgG-type AG A. The inter-assay coefficient 
of variation of A G A  test results was 10.6% and the 
intra-assay coefficient of variation was 5.7%.
Antireticulin antibodies
R l-type A R A  were detected using a standard indirect 
immunofluorescence (IIF) method21 with rat kidney 
and liver and mouse stomach mounted into a composite 
block as antigen substrates, and fluorescein iso- 
thiocyanate (FITC)-conjugated rabbit antihuman IgG 
(Dako) as the secondary antibody. The sera were inves­
tigated at dilutions o f 1:10 and 1:100 in PBS, and were 
considered ARA-positive if the characteristic R l-  
staining pattern was found in antigen substrates under a 
fluorescence microscope (Jenalumar SH 50; VEB Carl 
Zeiss, Jena, Germany [with ocular X6.3 and objective 
X25 and X50]). The specific pattern included staining of 
the fibers around the glomeruli and tubuli and around 
the blood vessels in the kidney section; staining of the 
nodular fibers in the portal areas o f the liver; and 
staining o f the fibers between the gastric glands, in the 
connective tissue, and in the muscular mucosa o f the 
stomach. Known ARA-positive and ARA-negative 
sera were used as controls.
Antiendomysium antibodies
IgA-type AEM  were measured by IIF, using the cry- 
ostat sections from the human umbilical cord as antigen 
substrate.22 Tissue sections were incubated with serum 
diluted 1:10 and 1:100 with PBS, and FITC-labelled 
rabbit antibody to human IgA (Dako) was used as 
secondary antibody. Under the fluorescence micro­
scope (Jenalumar SH 50; ocular X6.3, objective x25  
and X50) the presence of a honeycomb brilliant green 
network pattern along the peritubular muscle layer of 
vessels on umbilical cord was taken as positive. Known
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High frequency of antigliadin antibodies and absence of antireticulin 
and antiendomysium antibodies in patients with ulcerative colitis
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Abstract: Several authors have described an association 
between celiac disease (CD) and ulcerative colitis (UC), 
but this has not yet been established. The aim of our 
study was to examine the frequency of antigliadin 
antibodies (A G A ), antireticulin antibodies (A RA) 
and antiendomysium (AEM ) antibodies in the sera 
of patients with UC (n =  50), and to evaluate their 
correlation with clinical variables. Sixteen patients 
with irritable bowel syndrome (IBS) and 37 healthy 
individuals served as controls. An enzyme-linked 
immunosorbent assay was used for the detection of 
IgA- and IgG-type AG A. IgG-type A R A  were deter­
mined by an indirect immunofluorescence assay (IIF) 
using rat kidney, liver, and stomach as antigen sub­
strates. IgA-type AEM antibodies were measured by 
IIF, using cryostat sections from human umbilical cord. 
Seventeen of the 50 patients with UC (34%) were posi­
tive for IgA- or/and IgG-type AG A. There was no cor­
relation between the presence of A G A  and the duration 
or extent o f the disease, or disease activity. However, 5 
patients with both IgA- and IgG-types of A G A  had 
extensive colitis. Only 2 controls (4%) were positive for 
IgG-AGA. A R A  and AEM  were not detected in any 
individuals studied. Since the A R A  and AEM  test re­
sults were negative, we conclude that none of the UC  
patients in this series had CD.
Key words: ulcerative colitis, celiac disease, antigliadin 
antibodies, antireticulin antibodies, antiendomysium 
antibodies
Introduction
The pathogenesis of ulcerative colitis (UC) is still un­
known, although circumstantial evidence indicates that 
immune mechanisms may play an important role in 
mediating the gut lesion.1 Over the years, many differ­
ent diseases have been reported to occur concomitantly 
with inflammatory bowel disease (IBD).W The first 
association of celiac disease (CD) and UC was reported 
over 30 years ago by Salem and Truelove.4 Since that 
publication, several authors have described an associa­
tion of CD and UC,5-” although most of the reports are 
simply case reports; accordingly the clinical significance 
of this association is not yet established.
In CD, there is a permanent intolerance of the small- 
bowel mucosa to dietary cereals, mainly wheat, rye, 
barley, and oats. Ingestion of these cereal proteins 
results in villous atrophy, with crypt hyperplasia of the 
small-bowel mucosa, which recovers on a gluten-free 
diet. A  conclusive diagnosis of CD is based on the dem­
onstration of villous atrophy and crypt hyperplasia in 
small-bowel biopsy specimens.14-'5 As endoscopy and 
small bowel biopsy are invasive procedures, they cannot 
be considered feasible for screening patients for CD. 
Three types of antibodies— antigliadin antibodies 
(A G A ), antireticulin antibodies (A R A ), and anti­
endomysium (AEM ) antibodies however have been 
extensively investigated and suggested as screening 
tests for C D .1*-'*
The aim of our study was to examine the frequency of 
AG A, A R A , and AEM in patients with UC and to 
evaluate the correlations between these antibodies and 
various clinical features in patients with UC.
Patients
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A total of 103 individuals were investigated. Fifty serum 
samples were obtained from 50 consecutive unselected
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Tabel 3 Seosed haavand’iise ko liid i ja  Crohni tove ulafuse ja  ANCA esmemis'c vahe! :
Haigus ANCA-positiivsed patsiendid/patsientide iildarv
haavandiline koliit Crohni tobi
(n =  45/77) (n =  6/31)
Haiguse ulatus
proktiit 17/31
vasakpoolne koliit 12/23
pankoliit 16/23
Haiguse lokalisatsioon
ileiit 0 /7
koliit 1 /9
ileokoliit 5 /15
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Summary
A u to a n tib o d y  P ro file  o f In f la m m a to ry  
B ow e l Disease
To sludy an association between inflammatory 
bowel disease and autoimmunity the frequency and 
clinical value of antineulrophil cytoplasmic 
antibodies (ANCA) and several non-organ-specific 
antibodies were studied in sera from 77 patients 
with ulcerative colitis and in 31 patients with Crohn's 
disease. Thirty-two patients with the irritable bowel 
syndrome and 76 healthy persons served as 
controls. By indirect immunofluorescence - ANA, 
SMA, TMA or/and PCA were detected in 25 % of 
patients with ulcerative colitis, 26 % of patients with 
Crohn's disease and 12 % of healthy controls. ANCA 
were found in 58 % of patients with ulcerative colitis, 
19 % of Crohn's disease and 2 % of controls. AN A 
containing sera were further analysed by enzyme- 
linked immunosorbent assay for Sm, RNP, SS-A, 
SS-B, Scl-70 and Jo-1 antibodies. One sera reacted 
positively to the Scl-70 antigen. Our results support 
the idea that autoimmune mechanisms are more 
likely to be involved in the pathogenesis of ulcerative 
colitis than Crohn's disease.
Uurimistood on toetanud Eesti Teadusfond 
(grandid nr. 1925 ja  nr. 3045} ja  Liisa Kohmbuse 
Ma/estusfond, Stockholm, Rootsi
milles on vorreldud erinevate antikehade esinemis- 
sagedust eestlaste ja rootslaste hulgas ning on 
leitud, et ANA esines eestlastel statistiliselt oluliselt 
harvem kui rootslastel (7% versus 12%).
Ullatuslikult leiti Scl-70 antikehad kaua kestnud 
pankoliidi ja kaasneva autoimmuunse hepatiidiga 
patsiendil. Antikehad topoisomeraas I vastu, tuntud 
ka Scl-70-na, on uldiselt seotud difuusse sklero- 
dermiaga (5) ning voivad tekkida isegi kuid ja 
aastaid enne haiguse kliinilist avaldumist (7). 
Poletikulise soolehaiguse -ja/vSi autoimmuunse 
hepatiidi korral neid varem kirjeldatud ei ole.
Haavandilist koliiti podevatel haigetel leiti 
ANCA-d statistiliselt oluliselt sagedamini kui Crohni 
lobe podejatel (58% versus 19%). Enamikul juhtudel
oli tegemist p-ANCA-ga. Puudus korrelatsioon 
haiguse ulatuse ja ANCA esinemise vahel. 
Kirjanduses on viiteid (3), et ANCA voib aidata 
eristada haavandilist koliiti Crohni tovest, sest neid 
antikehi esineb vahestel Crohni tobe podejail.
Kaesolevas toos leiti ANCA 19%-l Crohni tobe 
podejqist ning seega voib jareldada, et ANCA 
kasutamine haavandilise koliidi srsitamisel Crohni 
tovest on p iira tud. Samas aga voib ANCA  
kattrbinaUioonis geneetiliste markeritega osutuda
subkliiniliseks haavandilise ko liid iga  seotud 
markeriks, sest on kirjeldatud positiivset seost HLA- 
DRB1 * 15 ja ANCA vahel (17). Crohni tove juhtudel 
esines ANCA vaid jamesoole haaratusega 
patsientide hulgas. See tulemus viitab jamesoole 
osatahtsusele ANCA tekkes ning toetab E. A. 
Vasiliauskase ja kaasautorite (15) arvamust, et 
ANCA-positiivsed haiged voivad esindada teatud 
kindlat alaruhma Crohni tobe podejate hulgas. 
Edasised uuringud ANCA antigeeni molekulaarse 
struktuuri ja funktsioonide osas on aarmiselt vaja- 
likud selgitamaks nende antikehade patogeneetilist 
osatahtsust poletikulise soolehaiguse korrol.
On arvatud, et autoimmuunmehhanismidel on 
olulisem osatahtsus haavandilise koliidi kui Crohni 
tove patogeneesis (11). Kaasnevate autoimmuun- 
haiguste ja erinevate antikehade sagedam 
esinemine haavandilise koliidi haigeil toetavad 
seda ideed. See tod kinnitab, et ANCA esineb 
statistiliselt oluliselt sagedamini haavandilist koliiti 
kui Crohni tobe podejail. Kuigi Crohni tove 
patogeneesis arvatakse olevat peamiseks haired 
T-raku aktivatsioonimehhanismide osas, on siiski 
voimalik, et teatud osal haigeist on haaratud ka 
antikehade vahendatud immuunmehhanismid.
label 1. ANA , SMA, TMA ja PCA esinem if sagedus haavdndilisf ko liiti (HK) ja Crohni tobe  
(CT)podejatB ning kontroUruhma i»ikuf«
A N A -, SMA-/ TWA- voi PCA-posHihrsele patsientide arv 
C T  ( n = 3 1 )  kontroilriihm  ( n = 1 0 8 )
1 1 
1
6 8
Antikehade
tiifer « K { n = 7 7 )
ANA 1:10 5
1:100 4
SMA 1:10
1.1 AA
5
! .  I wU
TMA 1:10J.1AA
1
1J: iu U 
PCA 1:10
1
2
1:100 1
Tofal 1 :10 13(17%)
1:100 6 (8%)
7 (23%) 
1 (3%)
1 
2
1
11 (10%)
2 (2%)
: / Tabel 2. Nautrofiilide tsiitoplasma anHkehade (ANCA) esinemissagedus haavandilist 
ko liiti (HK) ja  Crohni tabs (CT) pdde jd tii ning kohtro llruhmd isikute hulgas
Pahient Arv IIFA N C A +
•«(%)
Immunofluorestsenfsmuster 
p-ANCA c-ANCA p+c-ANCA
Haavandiline koliit 77 45 (58) 39 5 1
Crohni tobi 31 6(19) 5 1 0
Kontrollruhm 108 2(2) 2 0 0
cmtigeenide vdstaste (Sm, RNP, SS-A (Ro), SS-B (La), 
Scl-70, Jo-1) antikehade suhtes, kasutades Immuno 
Concepts RELiSA ENA multiparameelrilist 
testsusteemi (immuno Concepts, Sacramento, USA).
IgG ANCA maarati samuli IIF-meetodil (16), 
kasutades antigeenina etanoolis fikseeritud 
rieutrofiile. Seerumid lahjendati (1:20) PBS-is, 
sekundaarse antikehana kasutati fluorestseiiniga 
konjugeeritud inimese IgG-vastast antiseerumit. 
Koiki tulemusi hinnati fluorestsentsmikroskoobi 
[jenalumai) abil.
Tulemuste statistilise usaldusvaarsuse hindami- 
seks kasutati x2-testi koos Yatesi korrektsiooniga. 
Erinevust ruhmade vahel peeti statistiliselt oluliseks, 
kui P<0,05.
Too on heaks kiitnud Tartu Ulikooli Inimuuringute 
Eetika Komisjon.
Tulemused
IgG-tuupi ANA, SMA, TMA ja/voi PCA leiti 19-1 
77 haavandilist koliiti podejast (25%). Kaheksal 
31 (26%) Crohni tobe podejast esines ANA voi 
SMA. Kontrollruhmas oli ANA, SMA, TMA ja/voi 
PCA 13 isikul 108-st (12%) — tunduvalt harvemini 
kui haavandilist ko liiti podeja il (P<0,05). 
Antikehade esinemissagedus kontrollruhmas ja 
Crohni tobe podejail ei olnud statistiliselt erinev 
|P“ 0,1). Enamikul haavandilist koliiti ja Crohni tobe 
podejail esinesid need antikehad lahjenduses 1:10. 
Ainult heljal haavandilise koliidi haigel (1 mees ja 
I naine samaaegse autoimmuunse hepatiidiga, 2 
naist kaasnevate haigusteta) ja iihel Crohni tovega 
rneeshaigel (kaasnevate haigusteta) esines ANA  
tiitris 1:100, iihel haavandilise koliidiga naishaigel 
esinesid TMA ja PCA tiitris 1:100- Kontrollruhmas 
oli uhel naisel TMA ja uhel mehel PCA tiitris 1:100. 
AMA-d, ARA-d ega LKMA-d ei leitud uhestki 216 
uuritud seerumist. Andmed autoantikehade  
esinemise kohta on toodud tabelis 1.
12 ANA-positiivsest seerumist, mida uuriti edasi 
estanoolis fikseeritud HEp-2-rakkudel, reageerisid 
kolm seerumit positiivselt (homogeenne muster). 
Kaks seerumit parines fiaavandifise koliid iga  
naishaigeilf (uks autoimmuunse hepatiidiga ja uks 
kaasnevate haigusteta) ning uks Crohni tovega 
rneeshaigelt (kaasnevate haigusteta).
11 ANA-positiivset seerumit (uhe terve isiku 
seerum ei olnud enam kattesaadav) uuriti edasi 
ELISA abil Sm, RNP, SS-A, SS-B, Scl-70 ja Jo-1
antikehade suhtes. Uks seerum reageeris Scl-70 
antigeeni suhtes positiivselt. Tegemist oli 23-aastase 
pankoliiti podeva naispatsiendiga, kellel kaasneva 
haigusena oli ka autoimmuunne hepatiit.
IgG-tuupi ANCA leiti 45-1 77 (58%) haavandilist 
koliiti ja kuuel 31 (19%) Crohni tobe podejast 
(P<0,001). Kontrollruhmas esines ANCA kahel isikul 
108-st (2%): uhel soole arritussiindroomiga  
patsiendil ja uhel tervel isikul (P<0,001 haavandiline 
koliit vorreldes kontrollruhmaga, P<0,01 Crohni tobi 
vorre ldes kontro llruhmaga).U lekaalus oli 
p-ANCA, ainult viiel haavandilist koliiti ja uhel Croh­
ni tobe podejal oli c-ANCA. Uhel haavandilise 
ko liid iga  patsiendil esinesid molemat liiup i 
antikehad (vt. tabel 2). Kaheksal 45-st p-ANCA- 
posifiivsesf haavandilist koliiti podeva haige 
seerumist oli itnmunofluoreslsentsreaktsioon ka 
lumfotsuutide tuumade osas, mis nditas ANA  
samaaegset olemasolu (koikidel juhtudel kinnitati 
ANA olemasolu ka antigeensel kruostaatloigul). 
Uhe Crohni tove haige seerumis oli vaid nukleaarne 
helendus nii neutrofiilide kui ka lumfotsuutide osas 
ning kruostaatloigul kinnitus ANA olemasolu.
Nii haavandilise koliidi kui ka Crohni tove korral 
puudus seos haiguse ulatuse ja ANCA esinemise 
vahel (vt. tabel 3).
Arutelu
ANA, SMA, TMA ja PCA esinesid poletikulise 
soolehaigusega haigetel iildiselt harva ja madalas 
tiitris. Kuigi 25%-l haavandilist koliiti ja 26%-l Crohni 
lobe podejaist ning 12%-l kontrollruhma isikuist leiti 
eespool nimetatud antikehi, o lid  ainult 8%-t 
haavandilist koliiti, 3%-l Crohni tobe podejaist ja 
2%-l kontrollruhma kuulujaist need tiitris 1:100. G. 
N. Dalekos ja kaasautorid (2) on ago vostupidiselt 
leidnud ANA 41-1 80 (51 %-l) haavandilise koliidi 
haigest, kasutades ANA esmaseks maaramiseks 
HEp-2 rakuliini (positiivne ANA tiiter >-80). Nii suuri 
erinevusi ei saa seletada iiksnes metoodiliste 
isearasustega, seda enam, et kahel viiest meie 
uuritud ANA 1:100 positiivse haavandilise koliidiga 
patsiendisf oli koosnevana autoimmuunne hepatiit. 
Seega voib arvata, et ANA-d (lahjenduses 1:100) 
tuleb poletikulise soolehaigusega patsientidel ette 
harva. Voimalik, et erinev geneetiline taust ja 
keskkonnatingimused tingivad ANA madalama 
esinemissageduse Eesti patsientide hulgas. Meie 
tulemusi toetab ka R. Uibo ja kaasautorite t86 (14),
Karin  Kull, R iina Salupere -  Tarlu Ulikooli Sisekliinik
ICaja M e tsk iila , Raivo U ibo -  Tartu Ulikooli immunoloogia oppetool
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Rohketele uuringutele vaatamata on poletikulise 
soolehaiguse (haavandilise koliidi ja Crohni Idve) 
etioloogia ja patogenees siiani loplikult valja 
selgitamata. Siiski arvatakse, et immuunsiisteemil 
on poletikulise soolehaiguse patogeneesis keskne 
osci (1). Lisaks hairetele rakuliste immuunmehha- 
nismide osas esinevad muutused ka humoraalsetes 
kaitsemehhanismides (4, 12) ning seetottu on 
viimastel aastatel hakatud suurt tahelepanu 
poorama autoantikehade uurimisele.
Neutrofiilide tsutoplasma antikehad (ANCA), 
mis on tahtsal kohal susteemsete vaskuliitide ja 
giomerulonefriidi teatud vormide diagnoosimisel 
ja jalgimisel {6, 10), on tahtsad ka poletikulise 
soolehaiguse korral. Kaudse immunofluorest- 
sentsmeetodi alusel eristatakse kahte tuupi antikehi: 
p-ANCA, mille puhul reaktsioon lokaliseerub 
neutrofiilide tuumade umber, ja c-ANCA, mille puhul 
helendus esineb neutrofiilide tsutoplasmas. Neid 
antikehi leitakse 50-80%-l haavandilist koliiti ja 10- 
30%-l Crohni tobe podeja vereseerumis (9). ANCA 
tahendus poletikulise soolehaiguse patogeneesis 
ei ole teada, Arvatakse, et tegemist on markeriga, 
mis valjendab haireid immuunsiisteemi regulat- 
sioonimehhanismides.
Too eesmark on uurida haavandilist koliiti ja 
Crohni tobe podejail erinevate autoantikehade 
esinemissagedust ja kliinilist vaartust.
IJu rim ism a te rja l ja  -m e tood ika
Uurimisruhma kuulus 77 haavandilist koliiti (40 
meest ja 37 naist, keskmine vanus 43 aastat, 
vahemik 14—75 aastat) ning 31 Crohni tobe 
podejat (23 meest ja 8 naist, keskmine vanus 36 
aastat, vahemik 15—77 aastat). Haavandilise 
koliidi diagnoosimisel arvestati uldtunnustatud 
diagnostilisi kriteeriume: anamneesis veriroe, 
tijupiline koloskoopialeid ja morfoloogilised 
muutused biopsiapreparaadis. 31 haavandilist 
koliiti podeja! oli proktiit (poletikulised muutused 
ainult rektumis), 231 vasakpoolne koliit (muutused
ulatusid kuni colon transversum'i)teiVosari\\ ja 23-1 
pankoliit (protsess ulatus kaugemale colon  
transversum /keskosast). Kolektoomia oli eelnevalt 
tehtud 6 patsiendil. Crohni tove diagnoosimisel 
kasutati Lennard-Jonesi kriteeriume (8) ning haiguse 
ulatuse maaramiseks rakendati rontgenoloogilisi 
meetodeid ja koloskoopiat. Ileiit (muutused ainult 
peensooles) esines 7 Crohni tove haigel, 9 
patsiendil oli koliit (muutused koolonis caecum 1 ja 
rektumi vahel ilma peensoole voi seedetrakti ulaosa 
haaratuseta) ning 15-1 oli ileokoliit (muutused 
terminaaliileumis ja koolonis ukskoik kus caecum 1 
ja rektumi vahel). Uhel ileokoliidiga patsiendil 
esinesid perianaalne lesioon ja fistul. Kuuel haigel 
o li eelnevalt tehtud ileotsekaa lp iirkonna  
resektsioon, kahel hem ikolektoom ia, uhel 
kolektoomia koos ileostoomi rajamisega.
Kontrollruhma moodustasid 32 soole 
arritussundroomiga patsienti (16 meest ja 16 naist, 
keskmine vanus 38 aastat, vahemik 16-70 aastat) 
ja 76 tervet isikut (30 meest ja 46 naist, keskmine 
vanus 40 aastat, vahemik 17—79 aastat).
Seerumid sailitati temperatuuril -20 °C . IgG- 
tuiipi tuumavastased (ANA), mitokondritevastased 
(AMA), silelihaskoevastased (SMA), retikulHni- 
vastased (ARA), maksa-neeru mikrosoomide- 
vastased (LKMA), parietaalrakkudevastased (PCA) 
ja kilpnaarme mikrosoomidevastased (TMA) 
antikehad maarati kaudsel immunofluorestsents- 
meetodil (IIF) (13), kasutades antigeense 
substraadina erinevate kudede kruostaatloike. 
Seerumid lahjendati (lahjendus 1:10 ja 1:100) 
fosfaatpuhverlahuses (PBS), sekundaarse 
antikehana kasutati fluorestseiiniga konjugeeritud 
inimese IgG-vastast antiseerum it (Dako, 
Kopenhaagen, Taani). Koik ANA-d sisaldavad 
seerumid testiti etanoolis fikseeritud HEp-2-rakkudel 
(Immuno Concepts, Sacramento, USA) lahjenduses 
1:40 PBS-is ning immunoensuumimeetodil (ELISA) 
kuuel enam levinud ekstraheeritavate tuuma-
K. Kull, R. Salupere, K. Metsktila, R. Uibo. 
Autoantikehade esinemissagedus ja tahendus poletikulise soolehaiguse korral.
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of pANCA in healthy relatives of patients with 
UC may be explained by genetic heterogeneity 
(14,31), although some recent studies have not 
confirmed this (32,33). Associations between a 
positive pANCA result and HLA-DR2, and 
between a negative pANCA test result and HLA- 
DR4 have been found (34). However, an ensuing 
study has failed to show the present association 
between ANCA positivity and HLA-DR2 (35), 
and, therefore, the authors suggest that the 
conflicting results regarding an HLA-DR2 
association with UC may be caused by ethnic 
variation in linkage disequilibrium between 
HLA-DR2 and the actual susceptibility genes for 
UC. An alternative or additional explanation 
would be heterogeneity within UC.
In Estonia, the incidence of UC, and especially 
CD, appears to be rare. The reasons for such a 
low incidence are not known, but the different 
genetic background, dietary habits, and 
unknown environmental conditions of the 
patients studied, could not be completely ruled 
out. At the same time, there seem to be no 
significant differences in the prevalence of ANCA 
compared with the data observed in different
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In conclusion, the present study confirms that 
ANCA are common in IBD, and that patients 
from Estonia are not an exception. The presence 
of ANCA in a rather large amount of patients 
with CD patients limits their diagnostic value in 
distinguishing between UC and CD. 
Identification of the antigen(s) responsible for 
ANCA may facilitate the understanding of the 
underlying immunopathogenic mechanisms. 
Whether or not positive ANCA patients 
represent a subset of cases within a 
heterogeneous disease, requires the carrying out 
of further immunologic and genetic studies in 
Estonia and in other countries as well.
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positive sera were retested on Hep2 cell lines at a 
dilution of 1:40. Two female UC patients and 1 
male CD patient were found to be ANA positive. 
ANA in all of them produced a homogeneous 
staining pattern of the nucleus.
Of the 59 UC and 17 CD sera screened with 
ELISA, using proteinase-3, myeloperoxidase, 
lactoferrin, and cathepsin G as antigens, only 14 
of 76 (18%) sera were positive. Antibodies to 
proteinase-3 were detected in 5 UC and 1 CD 
sera, of which 3 UC and 1 CD sera scored positive 
for cANCA. One UC serum scored positive for 
pANCA and 1 UC serum had both types of 
ANCA. Antibodies to myeloperoxidase were not 
detected. Anti-lactoferrin antibodies were 
detected in 6 UC and 1 CD patients’ sera, of 
which 3 UC and 1 CD sera were pANCA positive, 
1 UC serum had both types of ANCA, and 2 were 
negative on IIF. Antibodies to cathepsin G were 
detected in 3 UC and 2 CD patients’ sera, of 
which 1 UC and 1 CD sera were pANCA positive, 
and 2 UC and 1 CD sera were negative on IIF 
(Table 4). Three patients with UC and 1 with 
CD had positive ELISA for two different antigens.
DISCUSSION
The present study showed that ANCA are quite 
often present in ulcerative colitis patients in 
Estonia. ANCA were detected in 49% of the 
patients with UC and in 24% of the patients with 
CD. The presence of ANCA in a rather great 
amount of patients with Crohn’s disease limits 
their diagnostic value in distinguishing between 
UC and CD. Therefore, we do agree with the 
findings of Broekroelofs et al (10), showing 
ANCA to be of limited or no value in 
distinguishing Crohn’s disease from ulcerative 
colitis.
The predominant ANCA staining pattern 
observed in our study was perinuclear, which is 
also affirmed by other authors in the case of IBD. 
However, it is distinct from vasculitis-associated 
pANCA, and it is not generally reactive with 
myeloperoxidase (4-5,22). In contrast to cANCA, 
which have shown to serve as highly sensitive 
and specific markers for Wegener’s 
granulomatosis (3,23,24), in IBD the pathogenetic 
role and clinical significance of pANCA is less 
favorably established. The problem is that ANCA 
are present only in 40-85% of the patients with
TABLE 4 Number of ANCA Positive Sera Detected by ELISA 
with Different Antigens
Ulcerative colitis Crohn’s disease 
(n=59) (n=17)
Antigen ELISA+ IIF+ ELI8A+ IIF+
Proteinase-3 5 5 1 1
Myeloperoxidase 0 0 0 0
Lactoferrin 6 4 1 1
cathepsin G 3* 1 2 1
* Fifty-six sera from patients with UC were studied.
UC (4-14), and most of the authors have failed to 
show either the correlation between ANCA and 
disease activity or ANCA and disease extent (4-
6,12,25). No correlation between ANCA and the 
duration or ANCA and the extent of IBD was 
found in our study either.
The other problem is that test sera may contain 
other antibodies, including antinuclear 
antibodies, which may result in a staining 
pattern not dissimilar to that of pANCA. 
Therefore, the screening of the sera with non­
specific staining patterns and, equivocally, 
ANCA positive for the presence of ANA, is useful 
until the antigen(s) responsible for ANCA are 
identified. When this is realized it may be 
expected that the problems associated with the 
recognition of ANCA can be overcome.
Whereas the antigen specificity of ANCA in IBD 
is still uncertain, antibodies to several 
constituents of neutrophils, including cathepsin 
G (26,27), lactoferrin (28), ^-glucuronidase (29) 
and, recently, bactericidaVpermeability-increasing 
protein (30) have been reported in some patients 
with IBD. None of these have been proven to be 
exclusively responsible for pANCA activity. In 
the present study, 18% of the serum samples 
were positive in specific ELISA assays. Though 
immunofluorescence and ELISA results did not 
correspond in our study, we support the findings 
that antigens other than proteinase-3, 
myeloperoxidase, lactoferrin and cathepsin G can 
be the targets for ANCA in Estonian patients 
with IBD, and remain to be evaluated in further 
investigations.
Since it now is believed that ANCA probably do 
not contribute to tissue injury in IBD, the finding
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TABLE 2 Distribution of Antineutrophil Cytoplasmic Antibodies in Patient 
and Control Sera Detected by Indirect Immunofluorescence
n IIF ANCA+ Immunofluorescence staining pattern
n (%) perinuclear cytoplasmic perinuclear and cytoplasmic
UC 59 29 (49) 22 6 1
CD 17 4 (24) 3 1 0
Controls 111 4 (4) 3 1 0
myeloperoxidase and proteinase-3 antibodies of 
IgG isotype (Wieslab AB, Lund, Sweden). Both 
kits were used according to the manufacturer’s 
instructions. A serum dilution of 1:80 was used 
in both assays. Alkaline phosphatase-labeled 
anti-human immunoglobulin G was used as a 
second antibody. The reaction was visualized 
using p-nitrophenyl phosphate as a substrate, 
and read at 405nm. Values exceeding the 
borderline (20 EU) were regarded as positive. 
The anti-lactoferrin and the anti-cathepsin G 
ELISAs were performed as originally described 
(20,21). Briefly, ELISA microtiter plates (Nunc, 
Roskilde, Denmark) were coated overnight, at 
4aC, with 5pg/ml human neutrophil lactoferrin 
(Sigma, St. Louis, Mo., USA), or 0.5pg/ml 
cathepsin G (Calbiochem, La Jolla, Calif., USA) 
in carbonate buffer (pH 9.6), and in 50mM 
sodium acetate with 150mM NaCl (pH 5.5), 
respectively. Plates were saturated with 1% 
bovine serum albumin in PBS (PBS/BSA), or 
with 5% swine serum albumin in PBS 
(PBS/SSA),, respectively. Controls and serum 
samples were diluted 1:100 in PBS/BSA 
1%/Tween 0,1% and incubated for 1 hour at 
room temperature. The bound IgG was detected 
using alkaline phosphatase-conjugated anti­
human IgG (Dako, Glostrup, Denmark), 
followed by p-nitrophenyl phosphate as a 
substrate.
Sera from 40 healthy persons were used as 
references to establish a base-line absorbance 
value, and defined as two standard deviations 
above the mean.
Statistical Amitysis
Statistical analysis of the data using the x2 test 
was performed. P<0.05 was considered to be 
significant. For comparing small numbers, 
Fisher’s exact test was performed.
RESULTS
IgG ANCA were detected by IIF on ethanol-fixed 
granulocytes in 29 of 59 (49%) patients with UC
TABLE 3 Relationship between Clinical Features of IBD 
and the Presence ol ANCA
ANCA positive patients/
total number o f patients
Ulcerative colitis Crohn's disease
29/59 4/17
Disease extent
Proctitis 11/25
Left-sided colitis 7/13
Extensive colitis 11/21
Disease localisation
Ileum 0/3
Colon 0/6
Ileum and colon 4/8
Duration of disease
<5 years 14/21 3/13
>5 years 15/38 1/4
and in 4 of 17 (24%) patients with CD (p=0.06). 
In the control group, serum samples from 1 of 25 
patients with irritable bowel syndrome, and 3 of 
86 healthy subjects were positive for ANCA 
(p<0.001 for UC compared to controls; p<0.01 
for CD compared to controls) (Table 2).
The predominant ANCA staining pattern seen by 
IIF in IBD was perinuclear (pANCA). Twenty- 
two of 29 positive patients with UC had pANCA, 
compared to 3 of 4 patients with CD. In 6 
patients with UC and 1 patient with CD, 
cytoplasmic staining (cANCA) was revealed. One 
patient with UC had both perinuclear and 
cytoplasmic staining (Table 2). In the controls, 
only 3 of 111 serum samples showed a weak 
perinuclear staining and 1 serum sample showed 
cytoplasmic staining.
In both UC and CD, there was no correlation 
between the presence of ANCA and the duration 
or extent of IBD (Table 3).
To ensure that ANCA in IBD indeed recognize 
cytoplasmic antigens, we screened all sera for the 
presence of ANA on rat liver slices. ANA (1:10) 
were detected in 5 UC patients and in 1 patient 
with CD; all patients were pANCA positive and 
without liver abnormalities. In the controls, 1 
serum sample was ANA positive. All 7 ANA
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the incidence of UC and CD varies in different 
countries (17,18), Estonia having one of the 
lowest rates among them. No published data on 
the epidemiology of IBD were available from the 
neighboring states of Estonia (Latvia and 
Lithuania) nor from Eastern European 
countries.
Since there are substantial epidemiological 
differences in the incidence of IBD between 
Estonia and European countries, only additional 
studies would yield more data about specific 
features of IBD in Estonia. The aim of our study 
is to: determine the prevalence and pattern of 
ANCA in Estonian patients with IBD; compare 
our results with the results from other countries; 
analyze the presence of ANCA in connection with 
the duration and extent of IBD; and, characterize 
the antigen specificity by enzyme-linked 
immunosorbent assay (ELISA), using 
myeloperoxidase, proteinase-3, lactoferrin and 
cathepsin G as antigens.
METHODOLOGY
Study Population and Serum Samples
Sera from a total of 187 patients were analyzed 
in the present study. Fifty-nine sera were 
obtained from the patients with UC and 17 from 
the patients with CD. For UC, the diagnostic 
criteria were based on a history of bloody stools, 
typical colonoscopy findings, and morphological 
changes in biopsy specimens. The extent of colitis 
in the patients with UC was evaluated with 
colonoscopy, and, in some cases, with barium 
enemas. For CD, the diagnostic criteria were 
followed according to the Lennard-Jones scoring 
table (19), and disease localization was evaluated 
by small-bowel roentgenograms, barium enemas, 
and colonoscopy. The duration of the disease was 
also considered. The clinical characteristics of 
the patients are shown in Table 1.
Twenty-five patients with irritable bowel 
syndrome (12 male, 13 female; mean age 38 
years) and 86 healthy persons (31 male, 55 
female; mean age 39 years) with no history of 
gastrointestinal or chronic disease served as 
controls. All sera were stored at -20°C until 
assayed.
Indirect ImimmofluorcscMce Assay (IIF)
The separation of peripheral blood neutrophils 
and the detection of ANCA by IIF according to
1 T A B L E  1 Cl i n i c al  C h a r a c t e r i s t i c s  of P a t i e n t s  w i t h  
I n f l a m m a t o r y  B o w e l  D i s e a s e  al  th e T i m e  of S e r u m  S a m p l i n g
Diagnoaia Ulcerative colitia Crohn's disease
(n«5B) <n-17)
Male/Female 28/31 13/4
Mean age (yean) 44 27
Diaease extent
Proctitis, n (%) 25(42)
Left-sided, n (%) 13(22)
Extensive, n (%) 21 (36)
Disease localisation
Ileum, (i (%) 3(18)
Colon, n (%) 6(35)
Ileum and coton, n (%) 8(47)
Duration of disease
<5 yean, n (%) 21(36) 13 (76)
>5 years, n (%) 38(64) 4(24)
the method described by Wiik (20) was 
performed with minor modifications.
Briefly, neutrophils were sep > ted from the 
peripheral blood of a healthy volunteer by Ficoll- 
Paque (Pharmacia Biotech AB, Uppsala, 
Sweden) centrifugation and dextran (BDH 
Chemicals Ltd, Poole, England) sedimentation. 
The buoyant neutrophils were recovered and 
washed. Cellular suspensions were smeared on 
slides and fixed in 96% ethanol for 5 minutes, 
dried at room temperature and stored at -20*C 
until the time of the assay, but not longer than 2 
weeks. The slides (coded patients or control sera; 
dilution 1:20) were incubated and stained with 
rabbit antihuman IgG - fluorescein 
isothiocyanate (FITC) conjugate (Dakopatts, 
Glostrup, Denmark).
The slides were evaluated by fluorescence 
microscopy. Positive and negative controls were 
included for all assays. Serum samples giving a 
typical perinuclear (pANCA) or cytoplasmic 
(cANCA) staining reaction with the neutrophils 
were regarded as positive.
Antinuclear antibodies (ANA) were detected by 
IIF on rat liver slices of 4pm at a dilution of 1:10 
and on ethanol-fixed HEp2 (Immuno Concepts, 
Sacramento, USA) cells at a dilution of 1:40 in 
phosphate buffered saline solution (PBS).
E n zy m e -H iiM  Im m unosorbent A ssay
Commercially available kits based on enzyme 
immunoassay were used for the analysis of
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ABSTRACT
BACKGROUND/AIMS: In Estonia, the incidence of ulcerative colitis and especially Crohn’s disease appears 
to be rare. Antineutrophil cytoplasmic antibodies (ANCA) are frequently found in ulcerative colitis 
but less frequently in Crohn’s disease, their pathophysiological significance is still unclear. 
METHODOLOGY: Fifty-nine serum samples from patients with ulcerative colitis, 17 with Crohn’s disease, 
25 with irritable bowel syndrome, and 86 healthy persons were studied. Sera were analyzed for the 
presence of ANCA by indirect immunofluorescence, and enzyme-linked immunosorbent assay for 
specific ANCA using different antigens was performed.
RESULTS: ANCA were detected in 29 of 59 (49%) patients with ulcerative colitis, 4 of 17 (24%) patients 
with Crohn’s disease, and in 4 of 111 (4%) controls. The immunofluorescence staining was mostly 
perinuclear (pANCA). There was no correlation between ANCA and the duration or extent of the 
inflammatory bowel disease. In specific enzyme-linked immunosorbent assays, only 14 sera elicited 
binding above the normal range.
CONCLUSIONS: Although the prevalence of ulcerative colitis and Crohn’s disease in Estonia is much 
lower than in European countries, there seem to be no differences in the presence of ANCA.
INTRODUCTION
Ulcerative colitis (UC) and Crohn’s disease (CD) 
are chronic inflammatory disorders of unknown 
origin. In either case of UC or CD, autoantibodies 
as well as associations with disorders of 
autoimmune origin can be found. Although the 
role of autoantibodies and the underlying 
pathogenesis in inflammatory bowel disease 
(IBD) remain unclear, it is generally believed 
that immune mechanisms are involved (1).
Antineutrophil cytoplasmic antibodies (ANCA) 
were first described in patients with 
glomerulonephritis (2). In 1985, it was shown 
that the antibodies directed against cytoplasmic 
components of neutrophils occur in Wegener’s 
granulomatosis and serve as sensitive and 
specific markers for active disease (3). More 
recently, serum immunoglobulin G (IgG) ANCA 
have been reported to be present in 40-85% of the
Hepato-Gastroenterology 1998; 45:2132-2137 
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patients with UC and in 4-40% of the patients 
with CD (4-14). By indirect immunofluorescence 
in IBD, the antigen localizes to the perinuclear 
area (pANCA) and is distinct from the 
cytoplasmic granular pattern (cANCA) seen 
characteristically in Wegener’s granulomatosis. 
The antigen(s) to which those antibodies are 
reactive in IBD are not clearly defined yet.
The basis for the present study is an 
epidemiological investigation of the incidence 
and prevalence of UC and CD in Tartu County, 
Estonia. A retrospective study for the years 1973- 
1993 revealed that IBD is not so commonly found 
in Estonia as it is in other countries, and that the 
reasons for such a low incidence in Estonia are 
not clear. The annual incidence of UC is 1.5 cases 
per 100,000, and of CD 0.27 per 100,000 (15,16). 
Studies of the epidemiology of IBD indicate that
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Background: When investigating susceptibility to inflammatory bowel disease (IBD), a multifactorial 
disorder with a genetic predisposition, polymorphisms of molecules with immunoregulatory function are 
of potential interest. This is the first time that the polymorphisms of HLA-DR and -DQ, tumour necrosis 
factor (TNF), E-selectin (CD62E), L-selectin (CD62L), and intercellular adhesion molecule 1 (ICAM-1, 
CD54) were determined in Estonians, a population with a low IBD incidence rate, and their occurrence 
investigated in subgroups of a total of S3 IBD patients. Methods: The reverse hybridization principle and 
sequence specific primers were used for HLA genotyping. To analyse the TNF and adhesion molecule 
polymorphisms, the polymerase chain reaction with subsequent restriction fragment length polymorphism 
or single-strand conformation polymorphism method was used. Results: In the subgroup of antineutrophil 
cytoplasmic antibody (ANCA)-positive ulcerative colitis (UC) patients we found a higher frequency of the 
TNF2 (20.8% versus 0.0% in ANCA-negative UC patients, P = 0.051) and HLA-DRB 1*15 allele (35.4% 
versus 15.7% in controls; P = 0.004). Of ANCA-positive UC patients 87.5% were carriers of one of these 
alleles (22.2% among ANCA-negative UC patients (P < 0.001, Pc = 0.039) and 51.4% among controls 
(P = 0.002). Specific typing of HLA-DRB1*15 alleles showed that the HLA-DRB1*1501 allele was 
responsible for the HLA-DRB I *15 association with ANCA-positive UC. Associations of ICAM-1, E- 
selectin, or L-selectin polymorphisms with IBD were not found. Conclusions: TNF2 and HLA-DRB 1*15 
alleles were associated with ANCA-positive UC in the investigated population. ANCA might be a useful 
marker, at least in some ethnic groups, for dividing IBD patients into genetically more homogeneous 
subgroups.
Key words: Adhesion molecules; antineutrophil cytoplasmic antibody; HLA class-II genes; inflamma­
tory bowel disease; polymorphism; tumour necrosis factor
PD Dr. rer. nat. Lothar Rink, Institute o f Immunology and Transfusion Medicine, Ratzeburger Allee 160, 
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Genetic predisposition, environmental factors and infectious agents are discussed as being in causal association with inflammatory bowel disease 
(IBD)—Crohn disease (CD) and ulcerative colitis (UC) (1- 
4). Despite extensive investigations, the aetiopathogenesis of 
IBD remains enigmatic. This may be partly due to the 
heterogeneity of the disease.
Persistent infiltration of the colonic mucosa with inflam­
matory cells and failure to down-regulate the inflammatory 
processes and other alterations of the immune system, 
mediating tissue damage, have been identified in patients 
with IBD in numerous studies. Accordingly, polymorphisms 
of genes involved in initiation and regulation of the immune 
response may be responsible for susceptibility to IBD.
Polymorphisms of the major histocompatibility complex 
(MHC) class-H genes are at the centre of interest in most 
studies investigating diseases with immunoregulatory ab­
normalities. With regard to IBD, significant positive associa­
tions have repeatedly been found between HLA-DRB 1*15 
and UC, especially with the antineutrophil cytoplasmic 
antibody (ANCA)-positive subgroup of patients (5-7). In 
patients with CD a positive association with HLA- 
DRB3*0301-DRB 1*1302 and HLA-DRl-DQw5 haplotypes 
has been observed (8-10). Recently, in studies from Germany 
and France, some other interesting associations between CD 
and MHC class-II alleles have been found: positive associa­
tion with HLA-DRB 1*07 and negative association with 
HLA-DRB1*03 (11,12). Nevertheless, many conflicting
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results exist, which may partly be explained by the differences 
in the investigated ethnic groups and clinical forms of the 
diseases. This shows that the aetiopathogenesis of IBD cannot 
be elucidated only by restriction to the MHC class-11 alleles. 
Other genes in the MHC locus, like tumour necrosis factor 
(TNF) genes, are of potential interest TNF-a and TNF-/f are 
proinflammatory cytokines that have been suspected of being 
involved in the pathogenesis of many human diseases (13). 
Many TNF-gene polymorphisms have been described in the 
last few years, some of which are probably correlated with 
differences in TNF-a or TNF-/? secretion (14). Because of the 
strong linkage disequilibrium between TNF and MHC class-II 
alleles (15), speculations could be made concerning the 
primary role o f the TNF gene polymorphisms in the 
aetiopathogenesis of MHC class-II-associated diseases. 
Furthermore, positive effects in the treatment of IBD with 
anti-TNF-a monoclonal antibodies support the assumption 
that TNF is involved in the pathogenesis of IBD, but the 
detailed mechanism remains unclear (16,17).
IBD is characterized by a persistent infiltration of the 
colonic mucosa by the inflammatory cells. The upregulation 
of the adhesion molecules is one of the physiologic require­
ments for the entry of these cells into the tissue (18,19). 
Recently, the genetic heterogeneity of intercellular adhesion 
molecule (ICAM)-l (CD54) in patients with IBD has been 
investigated. There was an increased frequency of the less 
common allele in the functionally important domain of 
ICAM-1 in the subgroups of patients with UC and CD, 
stratified by ANCA status (20). This supports the role of 
adhesion molecules in the aetiopathogenesis of IBD and 
suggests the existence of heterogeneity within IBD.
Because of the assumption that IBD is only in part 
genetically determined, the degree of importance of genetic 
markers for heterogeneous subgroups of IBD may vary. After 
dividing the UC and CD patients into more homogeneous
subgroups, the genetic associations may become visible 
(21,22). Apart from the discussions about the primary or 
secondary role of ANCAs in the pathogenesis of IBD, the 
presence of ANCAs is one of the suitable candidates for 
dividing the UC and CD patients into genetically homo­
geneous subgroups. ANCAs were found in 27%-83% of 
patients with UC and in 0%-25% of patients with CD (23). 
Although still under discussion, the frequent presence of 
ANCAs in healthy relatives of IBD patients and associations 
with developing pouchitis and persistence of ANCAs after 
colectomy indicate that the presence of ANCAs may rep­
resent an underlying genetically determined disturbance of 
immunoregulatory function (24-26). The presumable asso­
ciation of HLA-DRB 1*15 alleles with ANCA-positive UC 
but not with ANCA-negative UC and a different distribution 
of ICAM-1 alleles in subgroups of IBD patients, divided by 
the ANCA status, support this hypothesis (6,20).
The aim of this study was to investigate the distribution of 
polymorphisms of HLA class-II and TNF molecules in a 
novel population of IBD patients. In addition, we wanted to 
study the possible involvement of ICAM-1 and, for the first 
time, E-selectin (CD62E) and L-selectin (CD62L) poly­
morphisms in the pathogenesis and outcome of IBD. The 
usefulness of ANCAs for dividing IBD patients into more 
homogeneous subgroups with different genetic background 
was verified.
Subjects and Methods
Patients and controls
A total of 53 unrelated Estonian IBD patients, 33 with UC 
(16 male; median age, 37.3 years) and 20 with CD (15 male; 
median age, 36.0 years), were studied. For UC the diagnosis 
was based on a history of bloody stools, typical findings at 
colonoscopy, and morphologic changes in biopsy specimens.
Table I. Outline of adhesion molecule polymorphisms analysis
Polymorphism Method Primer sequence (5' to 3') PCR product
ICAM-1 (CD54)
Ig-like domain 3 PCR-SSCP Forward GATTGAAGAAGCCAGCAG 408 bp
(R/G241) Reverse GTCGTTGCCATAGGTGAC
Ig-like domain S PCR-RFLP Forward CCATCGGGGAATCAGTG 110 bp
(K/E469) Reverse ACAGAGCACATTCACGGTC
E-selectin (CD62E)
S'-untranslated region PCR-SSCP Forward TAACTAGCTACCCACGATTTCC 149 bp
(G/T98) Reverse ACTGACTTACCCAAAGTGAGAG
EGF-like domain PCR-SSCP Forward AGTAATAGTCCTCCTCATCATG 186 bp
(S/R128) Reverse ACCATCTCAAGTGAAGAAAGAG
Membrane domain PCR-SSCP Forward CAATTCTTCCTCATGACCTTTC 226 bp
(L/F554) Reverse CAAGACCATGACTTATCAATGAG
L-selectin (CD62L)
Lectin-like domain PCR-SSCP Forward TGTAAGTCTGCATAGGTCACAC 276 bp
(T/S49) Reverse TCAGTGAGAGATTTGTTGGTTC
EGF-like domain PCR-SSCP Forward CTTTGAGTACTAAAATGTAATCAC 198 bp
(F/L206) Reverse CCTAAGAAGAAGCAAAGAAAGG
Primers for amplification of the intercellular adhesion molecule (ICAM)-l Ig-like domains 3 and 5 as described by Vora et al. (31). Primer 
sequences to analyse E- and L-selectin polymorphisms were kindly provided by Dr. K. Wenzel (Charitfi, Berlin) (32).
PCR-SSCP= polymerase chain reaction-single-strand confirmation polymorphism; EOF= epidermal growth factor.
Scand i  Gastroenterol 1999 (10)
Genetic Polymorphisms in IBD 1027
For CD the diagnostic criteria were studied in accordance 
with the Lennard-Jones scoring table (27), and disease 
localization was evaluated by small-bowel roentgenograms, 
barium enemas, and colonoscopy. Seventy healthy Estonian 
blood donors served as controls. The distribution of age, sex, 
and ethnicity were comparable in the patients and controls. 
The study was approved by the Ethics Committee of the 
University of Tartu.
DNA extraction 
Genomic DNA was extracted from 10 ml venous ethyl- 
enediaminetetraacetic acid (EDTA) blood or from peripheral 
blood leukocytes (controls) with the QIAamp Blood Kit from 
Qiagen in accordance with the manufacturers’ procedure.
HLA-DRB and -DQB genotyping 
The HLA-DRB 1 and HLA-DQB1 genotyping was per­
formed by INNO-LiPA DRB and DQB key kit from 
Innogenetics. These HLA typing tests are based on the 
reverse hybridization principle. Amplified biotinylated DNA 
materia] is chemically denatured, and the single strands are 
hybridized with specific oligonucleotide probes immobilized 
on membrane-based strips. With the exception of 
DQBl*0201--*0202, all other DQB1 alleles could be distin­
guished. Although resolution at the allelic level is possible 
with the INNO-LiPA DRB key kit, only discrimination at the 
HLA-DRB 1*01, *15, *16, *03, *04, *11, *12, *13, *14, *07, 
*08, *09, and *10 allelic-group level was considered, except 
for the HLA-DRB 1 *0103 allele, which could be distinguished 
from other HLA-DRB 1*01 alleles. HLA-DRB 1*15 alleles 
were specificzilly typed with Micro SSP Allele Specific Class-
II DNA Typing Kit (One Lambda Inc.).
Detection o f ANCAs 
The separation of peripheral blood neutrophils and detec­
tion of ANCAs by indirect immunofluorescence assay were 
performed in accordance with the method described by Wiik 
et al. (28), wilh minor modifications.
TNF and adhesion molecule polymorphism analysis 
The detection of polymorphisms in the TNFa promoter at 
position -308 (TNF1/2) and in the TNF/? first intron 
(TNFB*l/2) with the help of PCR amplification and 
subsequent digestion with restriction enzyme Ncol were 
performed as described (29,30). Methods for identification 
of the adhesion molecule polymorphisms and primer 
sequences for amplification of the investigated gene frag­
ments are summarized in Table 1. PCRs were performed by 
using 30-ng template DNA in a final reaction volume of 50 |il 
in GeneAmp9600 (Perkin Elmer) thermal cycler. The 
amplification conditions were optimized by changing the 
annealing temperature and time or extension time for each 
investigated adhesion molecule gene region. The polymorph­
ism in exon 6 of the ICAM-1 gene (Lys:AAG or Glu:GAG at 
codon 469), coding for Ig-like domain 5, was identified
1 2  3 4 5 6 7 8
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Fig. 1. Representative single-strand conformation polymorphism 
(SSCP) analysis of the L-selectin epidermal growth factor (EGF)- 
like domain. An amplified 198-bp gene fragment was separated on 
PhastGel Homogeneous 20% gel. The amino acid polymorphism at 
codon 206 (F/L206) is caused by change from thymine to cytosine at 
nucleotide position 668, which results in a band shift in the 
electrophoretic analysis. Lanes 1, 2, and 3: heterozygous TC668. 
Lanes 4, 5, 6, and 8: homozygous TT668. Lane 7: homozygous 
CC668.
through incubation of the amplified 110-bp ICAM-1 exon 6 
gene fragments with the restriction enzyme BstUl. The 
presence of the BstUl restriction site (CG^CG) resulted in 
86 and 24 bp fragments. Fragments were analysed by 
electrophoresis on 4% NuSieve agarose gels and by subse­
quent staining of the gels in 0.1% ethidium bromide.
For the identification of the polymorphisms in all other 
amplified adhesion molecule gene regions, a single-strand 
conformation polymorphism (SSCP) method was used. The 
fragments were denatured and run on non-denaturing 12.5% 
or 20% polyacrylamide gels (Homogeneous PhastGels) from 
Pharmacia Biotech. The conditions for the horizontal electro­
phoresis and silver staining were optimized for each gene 
fragment and were performed semi-automatically with the 
PhastSystem (Pharmacia LKB Biotechnology AB). Fig. 1 
shows the detection of the polymorphism in the L-selectin 
epidermal growth factor (EGF)-like domain by PCR-SSCP 
analysis as an example of this method. To verify the SSCP 
results, the PCR products were sequenced.
Statistical analysis
Patients with UC, grouped together, and patients with CD, 
grouped together, were compared with controls. Associations 
with subsets of UC and CD patients, divided on the basis of 
ANCA status, were also evaluated. The statistical significance 
was tested by the chi-square test. The Fisher exact test was 
used when appropriate (that is, expected number <  5). 
Significance was taken as P < 0.05. By the correction of P
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Table II. Less common allele frequencies (percentage) of adhesion 
molecule genes in patients and controls
Controls UC patients CD patients 
Polymorphism (n = 70) (n = 33) (n=20)
ICAM-1
Ig-like domain 3 14.3 12.1 20.0
Ig-like domain S 42.1 48.5 52.5
E-selectin
5'-untranslatea region 28.6 33.3 32.5
EGF-like domain 13.6 12.1 20.0
Membrane domain 3.6 7.6 2.5
L-selectin
Lectin-like domain 4.3 3.0 5.0
EGF-like domain 22.1 18.2 15.0
ICAM = intercellular adhesion molecule; EGF= epidermal 
growth factor; UC = ulcerative colitis; CD = Crohn disease.
values, the recommendations of Svejgaard & Ryder (33) were 
taken into consideration. The correction factor for HLA- 
DRB 1 and HLA-DQB1 alleles was 12 (extremely infrequent 
alleles, ranging from 0 to 2, were not included in the number 
of comparisons). In the subgroups of UC or CD, stratified by 
ANCA, the correction factor was 24. In the phenotypic 
combination analysis the P values were corrected by a factor 
of 48. A corrected P value is designated Pc. The odds ratio 
(OR) as a measure of association was calculated using a 
Haldane modification as suggested by Svejgaard & Ryder 
(33).
Results
ANCA
ANCAs were detected in 27 of 53 patients (50.9%). Within 
UC and CD patients the occurrence of ANCAs differed. 
ANCA positiviiy rate in the 33 UC patients was 72.7% 
(69.7% perinuclear staining pattern and 3.0% cytoplasmic 
staining pattern). Only 3 of 20 CD patients were ANCA-
Table III. Allele frequencies and carriage rates (both in percentages) 
of tumor necrosis factor (TNF) polymorphisms
Allele frequencies . . . .  _
______________  Allele 2
Polymorphism Allele 1 Allele 2 carriage rate
TNF 1/2
Controls (n = 70) 83.6 16.4 30.0
UC patients (n = 33) 84.8 15.2 24.2
ANCA-pos. UC (« = 24) 79.2 20.8 33.3
ANCA-neg. UC (n = 9) 100.0 0.0 0.0
CD patients (n = 20) 80.0 20.0 40.0
TNFB*l/2
Controls (n = 70) 32.9 67.1 92.9
UC patients (n = 33) 28.8 71.2 78.8
ANCA-pos. UC (n =24) 33.3 66.7 79.2
ANCA-neg. UC(/i = 9) 16.6 83.4 77.8
CD patients (n = 20) 37.5 62.5 95.0
ANCA = antineutrophil cytoplasmic antibody; CD= Crohn dis­
ease; UC = ulcerative colitis.
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Table IV. Frequencies (%) of HLA-DRB 1 alleles in controls and 
patients
HLA-DRB I*
Controls 
(n = 70)
UC patients 
(n = 33)
CD patients 
(n = 20)
*01t 11.4 7.6 22.5
*0103 0.0 1.5 0.0
*03 15.7 9.1 17.5
*04 5.7 4.5 5.0
*07 11.4 12.1 5.0
*08 5.7 4.5 7.5
*09 0.0 1.5 5.0
*10 0.7 0.0 0.0
*11 14.3 9.1 20.0
*12 2.9 6.1 2.5
*13 11.4 10.6 7.5
*14 0.7 1.5 2.5
*15 15.7 28.8* 2.5 §
*16 4.3 3.0 2.5
UC=ulcerative colitis; CD = Crohn disease, 
t  Other than HLA-DRB1*0103.
$ Compared with controls: P = 0.028.
§ Compared with controls: P = 0.027.
positive (15.0%), all of them with a perinuclear staining 
pattern.
Adhesion molecule polymorphisms
The observed allele frequencies of investigated adhesion 
molecule polymorphisms in the control group and in the 
groups of patients with UC or CD are shown in Table II. There 
were no statistically significant differences in aliele frequen­
cies between controls and patients with UC or CD or the 
patients considered as one group.
Also after dividing the patients into subgroups on the basis 
of ANCA status, no significant differences were observed. 
Increased frequencies of the uncommon R241 ICAM-1 allele 
in the ANCA-negative UC and ANCA-positive CD subgroups 
of patients, described by Yang et al. (6,20), were not found in 
our study.
TNF polymorphisms
Allele frequencies and carrier rates of the TNF 1/2 poly­
morphism (in the TNFa promoter at position -308) and 
TNFB*I/2 polymorphism (in the TNF/? first intron) were 
similar in patients with UC and CD and control individuals 
(Table III). Subgroup analysis showed borderline significant 
differences in the frequency of the uncommon TNF2 allele in 
the ANCA-positive and ANCA-negative subgroups of pa­
tients with UC (20.8% versus 0.0%, respectively; P = 0.051). 
This fact gained more importance with regard to other factors 
associated with ANCA positivity, as discussed later.
The TNFB*i allele was in linkage disequilibrium with the 
TNF2 allele (P <  0.00001). Therefore, the frequency of the 
TNFB*1 allele tended to show similar differences between 
ANCA-positive and ANCA-negative UC patients, but this 
trend did not reach statistical significance.
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H  UC ANCA neg. 
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0.004.
HLA-DRB1*03 HLA-DRB1*11 HLA-DRB1*15
Fig. 2. HLA-DRB1*03, *11, and *15 allele frequencies (percentage) 
in the control group and in the antineutrophil cytoplasmic antibody 
(ANCA)-negative and ANCA-positive subgroups of ulcerative 
colitis (UC) patients.
HLA class-II genes 
The distribution of HLA-DRB 1 alleles is shown in Table 
IV. HLA-DRB 1*15 allele frequency was increased in UC 
patients compared with controls (28.8% versus 15.7%; 
OR = 2.16; P = 0.028). By contrast, the HLA-DRB 1*15 allele 
frequency was decreased in patients with CD (2.5% versus 
15.7%; OR = 0.20; P = 0.027). There was only one carrier of 
this allele among CD patients (5.0% versus 31.4% in the 
control group; OR = 0.17; P = 0.017). The apparently in­
creased proportion of CD patients carrying the HLA- 
DRB 1*01 allele did not attain statistical significance com­
pared with controls (45.0% versus 22.9%; P = 0.051), 
possibly due to the small sample size. The HLA- 
DRB 1*0103 allele was infrequent in our population, so no 
conclusions about the role of this allele in the pathogenesis of 
IBD, as suspected in some studies, could be drawn (34).
When patients were stratified by ANCA status, a different 
distribution of the HLA-DRB 1 alleles in subgroups of UC 
patients was identified. Increased frequency of HLA- 
DRB1*15 alleles in UC patients could be reduced to the 
association of HLA-DRB 1*15 alleles with ANCA-positive 
UC (35.4% versus 15.7% in controls; OR = 2.93; P = 0.004). 
ANCA-negative UC patients had approximately the same 
HLA-DR*15 allele frequency as controls (11.1% versus 
15.7%). Interestingly, HLA-DRB 1*03 and HLA-DRB1*11 
alleles were found only in UC patients with ANCAs and not 
among ANCA-negative UC patients (Fig. 2).
To support the hypothesis that the HLA-DRB 1*1502 allele 
may be responsible for the association of HLA-DRB 1*15 
alleles with UC, and particularly with their ANCA-positive 
subgroup, specific typing of HLA-DRB 1*15 alleles was 
performed. HLA-DRB1*1501 and -DRBl*1502 alleles 
were both increased in the groups of UC and ANCA-positive 
UC patients compared with controls, but the HLA- 
DRB 1*1502 allele was infrequent in the population studied 
(Fig. 3) and was not the factor explaining the association of 
HLA-DRB1*15 alleles with UC and ANCA-positive UC.
As expected, the HLA-DR3-DQ2 haplotype was in strong 
linkage disequilibrium with the uncommon TNF2 allele 
(P <  0.00001). HLA-DR-DQ/TNF1/2 phenotypic combina­
tion analysis showed an interesting pattern in the distribu­
tion of possible phenotypes. In the group of UC patients the 
HLA-DR3-DQ2 haplotype was not found without the 
TNF2 allele (15.0% of HLA-DR3-DQ2 carriers in the con­
trol group). And more often the TNF2 allele carriers were 
presented without the HLA-DR3-DQ2 haplotype in TNF2- 
positive UC patients (37.5% versus 19.0% in the control 
group).
HLA-DQB1 alleles were found to be associated with UC or 
CD only in relation to strong linkage disequilibrium with 
HLA-DRB 1 alleles, always with lower P values.
40%
30%
20%
10%
|HLA-DRB1*1501 
«HLA-DRB 1 * 1502
Control ANCA-pos. ANCA-neg.
Fig. 3. HLA-DRB1*1501 and DRB1*1502 allele frequencies 
(percentage) in the control group and in the antineutrophil 
cytoplasmic antibody (ANCA)-negative and ANCA-positive sub­
groups of ulcerative colitis (UC) patients.
Control UC ANCA neg. UC ANCA pos.
JJ|HLA-DRB!*15/TNF2 - / +  g|HLA-DRBl*15/TNF2 + / -  
ggHLA-DRBl»15/TNF2 + /+  gf§HLA-DRBl*15/TNF2 - / -
Fig. 4. The proportion of HLA-DRB l*15/tumour necrosis factor 
(TNF)2 phenotypic combinations in the control group and in 
ulcerative colitis (UC) patients divided on the basis of antineutrophil 
cytoplasmic antibody (ANCA) status.
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ANCA, HLA-DR, and TNF1/2 triangle
Both TNF2 and HLA-DRB 1*15 alleles showed an in­
creased frequency in the ANCA-positive subgroup of UC 
patients. The distribution of four phenotypic combinations of 
the HLA-DRB 1*15 and TNF2 alleles was very different in 
the control group and in the UC patient groups divided by 
ANCA status (Fig. 4); 87.5% of the ANCA-positive UC 
patients were carriers of at least one of the HLA-DRB 1 * 15 or 
TNF2 alleles, compared with 22.2% of the ANCA-negative 
UC patients (OR = 18.97; P <  0.001, Pc = 0.039), and 51.4% 
of the controls (OR = 5.81; P = 0.002). To further investigate 
the associations of these two factors with UC and its ANCA- 
positive subgroup, various two-by-two tables were generated, 
involving stratification of each of the two factors against the 
other. This analysis of the four phenotypic combinations 
showed a significant association of HLA-DRB 1*15 with UC 
(OR = 3.29; P = 0.015) and ANCA-positive UC (OR = 8.59; 
P <  0.001, Pc = 0.018) in TNF2-negatives. The TNF2 allele 
was associated with ANCA-positive UC in HLA-DRB 1* 15- 
negatives (OR = 5.10; P = 0.027).
Discussion
The distribution of the MHC class-II and TNF alleles in a 
novel subpopulation of IBD patients was studied. The 
investigation of Estonian UC and CD patients is of particular 
interest because of the very low UC and CD incidence rates 
(1.5 and 0.28 per 100,000, respectively) in this country as 
compared with other European populations (overall incidence 
of UC and CD, 10.4 and 5.6 per 100,000, respectively) 
(35-37).
We observed associations of the investigated MHC class-II 
alleles and TNF1/2 alleles with subgroups of patients. Both 
the TNF2 and HLA-DRB 1*15 alleles were associated with 
ANCA positivity in patients with UC. The usefulness of 
ANCA as a marker of genetic heterogeneity in ulcerative 
colitis is still being discussed (38-40). Our data indicate that 
TNF2 and HLA-DRB 1*15 alleles themselves or, more likely, 
in strong linkage with some other gene loci, might be genetic 
markers for the susceptibility to develop ANCA-positive UC. 
The role o f these markers could vary in different ethnic 
groups because of the different linkages with the primary 
susceptibility genes. Although there is strong evidence to 
support the involvement of TNFa in the pathogenesis of IBD, 
a primary role of the TNF1/2 polymorphism in developing 
ANCA in UC patients or ANCA-positive UC is questionable. 
The TNF1/2 polymorphism was not responsible for striking 
differences in the capacity of cells to produce TNFa, as shown 
by Bouma et al. (14). However, studies with larger sample 
size and with different cell stimulants must be performed to 
draw final conclusions.
The association of HLA-DRB1*15 alleles with ANCA- 
positive UC is not a generally accepted phenomenon. 
Opposing findings might be attributed to the variability in 
HLA-DRB 1*15 allelic frequencies in different ethnic groups.
HLA-DRB 1*1502, the commonest allele in Japanese and 
Jewish populations, is supposed to be responsible for the 
HLA-DRB1*15 association with UC (5,34,41). However, 
the HLA-DRB 1*15 allele frequency was also increased in 
Dutch and Spanish white UC patients (7,42). To test this 
hypothesis, specific typing of HLA-DRB1*15 alleles was 
carried out. There was a low frequency of the DRB 1*1502 
allele in our population, and the association of HLA- 
DRB 1*15 alleles with ANCA-positive UC could not be 
attributed to the HLA-DRB 1*1502 allele. In view of this fact 
and the conflicting results concerning HLA-DRB1*15 asso­
ciation with ANCA-positive UC, a linkage between HLA- 
DRB1*15 and susceptibility genes for ANCA-positive UC, at 
least in some ethnic groups, is a plausible explanation (39).
Remarkable dissimilarities were found in the distribution of 
HLA-DR-DQ/TNF1/2 phenotypic combinations in controls 
compared with patients with UC. There is some disagreement 
with regard to the role of the well-known HLA-DR3-DQ2- 
TNF2 haplotype in the outcome of IBD. On the one hand, a 
protective effect of the HLA-DR3-DQ2 haplotype against 
IBD has recently been reported (42,43). On the other hand, 
an expected similar negative correlation between the TNF2 
allele and IBD has not been observed (44,45). Moreover, the 
association of the TNF2 allele with ANCA-positive UC has 
been shown by others and in this study (40,46). We suspect a 
different influence of the TNF2 allele and HLA-DR3-DQ2 
haplotype on the outcome of IBD, as has recently been shown 
for fistulizing CD (47). The analysis of the HLA-DR3-DQ2/ 
TNF2 phenotypic combinations showed an increased fre­
quency of the — /+  phenotypic combination and decreased 
frequency of the + / -  combination in UC patients. The 
number of phenotypically informative individuals was very 
small because o f the strong linkage disequilibrium between 
HLA-DR-DQ and TNF1/2, Given the population size of 
Estonians (1.5 millions) and the low incidence of IBD, it is 
very difficult to obtain statistically significant results in this 
population. A study with sufficient power would require, 
multicentric collaboration or selection of patients with a 
special genetic background.
This is the first study investigating the possible involve­
ment of E-selectin and L-selectin, in addition to other 
adhesion molecule polymorphisms (ICAM-1), in the patho­
genesis of IBD. We could not confirm the previously 
observed increased frequency of the uncommon ICAM-1 
R241 allele among ANCA-negative UC and ANCA-positive 
CD patients (6). This discrepancy might be attributed to 
ethnic differences. In addition to the differences in the UC and 
CD incidence rates in the Estonian population, there was a 
markedly higher frequency of the less common R241 allele in 
our control group (14.3%) than in the control group used by 
Yang et al. (6.4%) (6). Investigated polymoiphisms in the 
gene regions encoding for E-selectin and L-selectin seemed to 
have no influence on the aetiopathogenesis or outcome of 
IBD.
In conclusion, we observed statistical associations between
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HLA-DRB 1 and TNFa polymorphisms and subgroups of IBD 
patients. Statistical associations provide no evidence of a 
pathogenic role but suggest an involvement in the pathogen­
esis. These polymorphisms might be directly associated with 
IBD or could be linked to certain susceptibility genes. At least 
in some ethnic groups, ANCA appears to be a useful marker 
in combination with genetic markers such as HLA-DRB 1*15 
alleles, by dividing IBD patients into more homogeneous 
subgroups with putative disparate pathogenic pathways. The 
HLA-DR3-DQ2 haplotype and the TNF2 allele, in strong 
linkage disequilibrium with each other, might have different 
influences on the outcome of IBD. Further studies with more 
patients are needed to test this hypothesis.
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